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The development of new chemical entities, novel drug delivery systems and alternative routes to deliver 
antiretrovirals (ARVs) are being explored to overcome the numerous limitations associated with HIV & 
AIDS drug therapy. Drug delivery via the buccal route has recently emerged as a promising alternative to 
delivery via the oral route. Drugs can directly enter the systemic circulation, bypass gastrointestinal 
degradation and first-pass hepatic metabolism, thereby increasing bioavailability. Although buccal 
permeation investigations with ARV drug solutions have confirmed their trans-buccal delivery potential, 
studies on their formulation into delivery systems are lacking. Rapid drug degradation of didanosine (DDI) 
in the gastrointestinal tract due to acid hydrolysis, together with the need for repetitive dosing, its short 
half-life, low oral bioavailability and dose-related toxicity, make DDI a suitable model ARV drug for buccal 
delivery. The aim of this study was therefore to design, evaluate and optimize the preparation of novel 
polymeric films for buccal delivery of DDI as a model ARV drug.  
 
Multipolymeric monolayered films (MMFs) with drugs and polymers of opposing solubilities will offer 
several advantages for the controlled release delivery of DDI via the buccal route. The first aim of this 
study was therefore to prepare DDI loaded films with polymers of opposing solubilities and to undertake 
extensive physico-chemical/mechanical and molecular modelling characterisations. MMFs were prepared 
via a simplified solvent casting/evaporation method and characterised in terms of drug content uniformity, 
in vitro drug release, in vitro permeation, histomorphology, mucoadhesivity, mechanical properties and 
surface pH. Uniform drug content (91–105 %) with low variability was obtained for all films. Co-blending of 
DDI, Hydroxypropyl methylcellulose (HPMC) and Eudragit®RS 100 (EUD) (1:1:10) was required to 
achieve controlled drug release. The buccal permeability potential of DDI from the MMFs was successfully 
demonstrated with a permeability coefficient of 0.72 ± 0.14 × 10−2cm/h and a steady state flux of 71.63 ± 
13.54 µg/cm2h. Films had acceptable mucoadhesivity (2184 mN), mechanical strength (0.698 N/mm2) and 
surface pH (6.63). The co-blending-co-plasticization technique for preparation of MMFs containing EUD 
and HPMC was justified via static lattice molecular mechanics simulations (SLAS). The mechanism 
inherent to the mucoadhesive and drug release profile performance of the MMFs was also elucidated via 
SLAS wherein a close corroboration among the in vitro–in silico (IVIS) data was observed. These 
extensive physico-mechanical and molecular atomistic studies confirmed the use of MMFs containing DDI, 
HPMC and EUD as a buccal delivery system. 
 
A large portion of ARV limitations are related to inadequate drug concentrations reaching the site of action 
and low oral bioavailability. Recent developments in the field of buccal drug delivery show an increased 
interest towards nano-enabled drug delivery. The advantages of buccal drug delivery can be combined 
with that of the nanoparticulate delivery systems to provide a superior delivery system in terms of 
enhanced bioavailability and drug targeting. The second aim of the study was therefore to design, evaluate 
and optimize the preparation of novel nano-enabled polymeric films for buccal delivery of DDI as a model 
ARV drug. Solid lipid nanoparticles (SLNs) were prepared via a hot homogenization technique followed by 
ultrasonication and were characterized in terms of size, surface charge, morphology and drug entrapment 
efficiency (EE). Optimal parameters for preparation of the DDI loaded SLNs were identified before 
preparing and comparing the physico-mechanical properties of nano-enabled multipolymeric monolayered 
films (MMFs) to conventionally prepared MMFs. Glyceryl tripalmitate in combination with Poloxamer 188 
as a surfactant was identified as being most suitable for preparation of DDI-loaded SLNs. Optimized 
particles exhibited a desired particle size (201 nm), polydispersity index (0.168), zeta potential (-18.8 mV) 
and formulation pH (5.5). Conventional and SLN entrapped MMFs were prepared via solvent 
casting/evaporation using EUD and HPMC in combination and characterised in terms of drug content, drug 
release, permeation, mucoadhesion and mechanical properties.  Drug release from the nano-enabled films 
was higher, with 56 % released in the 1st hour as opposed to 20 % for the conventionally loaded MMFs. 
DDI was released from the buccal film and permeated across the mucosa as evidenced by steady state 
       ix 
 
   
 
flux values of 71.63 ± 13.54 µg/cm2h and 74.39 ± 15.95 µg/cm2h, for the conventional and nano-enabled 
MMFs, respectively. SLNs did not adversely affect the flux and confirms the potential of DDI being 
delivered via the buccal route using nano-enabled MMFs. Conventional MMFs exhibited higher 
mucoadhesion (1425.00 ± 77.15 mN) and mechanical strength (0.6976 ± 0.064 N/mm2) than nano-enabled 
MMFs (914.33 ± 68.09 mN and 0.4930 ± 0.003 N/mm2). These physico-mechanical studies confirm the 
potential use of nano-enabled MMFs containing DDI-loaded SLNs as a buccal delivery system and serves 
as a platform for future formulation optimisation studies.  
 
These results confirm the feasibility of preparing films for buccal delivery of DDI as a model ARV drug that 
may ultimately lead to optimized drug therapy for HIV & AIDS patients.  
 
 
Key words: Antiretrovirals, Didanosine, Buccal delivery, Films, Co-blended polymers, Permeation, 
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This chapter provides an introduction and summarizes the background to the study. It 
outlines the challenges encountered with current antiretroviral therapy and buccal drug 
delivery systems and explores the rationale for and novelty of the study. It also covers 
the aim and objectives of the study. 
 
1.2 BACKGROUND TO THE STUDY  
 
Human Immunodeficiency Virus (HIV) infection and Acquired Immune Deficiency 
Syndrome (AIDS), commonly referred to as HIV & AIDS, have remained one of the 
leading causes of death worldwide, and is a major cause of mortality in sub-Saharan 
Africa (Merson et al., 2008, WHO, 2013). While antiretrovirals (ARVs) have proven to 
be useful in the treatment and management of HIV & AIDS, several disadvantages, 
including extensive first pass metabolism, gastrointestinal degradation, low 
bioavailability and short half-lives (Li and Chan, 1999), limit their efficacy. Large doses, 
complex dosing regimens and multiple drugs contribute to reduced patient compliance 
(Chandwani et al., 2012). Poor drug solubility and limited membrane permeability also 
present formulation difficulties (Sharma and Garg, 2010), resulting in more effective 
treatment strategies needing to be developed. 
 
The development of new chemical entities, novel drug delivery systems (NDDS) and 
alternative routes to deliver ARVs (Ojewole et al., 2008) are being explored to 
overcome these limitations. Novel drug delivery systems for ARVs receiving increased 
attention include sustained release matrix tablets (Sánchez-Lafuente et al., 2002b) 
ceramic implants (Benghuzzi, 2000), liposomes (Dubey et al., 2010) and nanoparticles 
(Kuo and Chung, 2011b). Alternate routes for ARV delivery under investigation include: 
transdermal (Gerber et al., 2008), nasal (Carvalho et al., 2013), vaginal (Johnson et al., 
2010) and the buccal route (Ojewole et al., 2012, Xiang et al., 2002).  
 
Drug delivery via the buccal route has recently emerged as a promising alternative to 
delivery via the oral route. Drugs can directly enter the systemic circulation, bypass 
gastrointestinal degradation and first-pass hepatic metabolism, thereby increasing 
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bioavailability (Hoogstraate and Wertz, 1998). The buccal mucosa is easily accessible 
and more permeable than skin (Squier and Hall, 1985), making this a suitable route for 
drug delivery in pediatrics and geriatrics. Formulating a drug into a controlled release, 
mucoadhesive buccal dosage form may further improve drug delivery and patient 
compliance (Morales and McConville, 2011). Several ARV drugs may therefore benefit 
from delivery via the buccal route. 
 
To date, studies reporting on the delivery of ARVs via the buccal route remain limited. 
The majority of work thus far has focussed on in vitro drug permeability studies using 
only drug solutions of zalcitabine (Shojaei et al., 1999, Xiang et al., 2002), didanosine 
(Ojewole et al., 2012, Rambharose et al., 2013) and tenofovir (Rambharose et al., 
2013). Furthermore, the only available research paper on buccal polymeric dosage 
forms of ARVs is of zidovudine polymeric patches recently produced by Reddy et al. 
(2012). Characterization studies were limited and do not include critical parameters 
such as in vitro permeation or mechanical properties. ARV buccal drug delivery 
systems have not been comprehensively investigated or characterised, and a clear 
need exists for formulation optimization in this field. 
 
Various mucoadhesive buccal dosage forms being investigated for different classes of 
drugs, include adhesive tablets (Cappello et al., 2006), gels (Ayensu et al., 2012b), 
ointments (Petelin et al., 2004), patches (Vasantha et al., 2011), and more recently, 
films (Abruzzo et al., 2012, Sievens-Figueroa et al., 2012). Polymeric films are flexible 
and comfortable, and can circumvent the relatively short residence time of oral gels on 
the mucosa (Ahn et al., 2001, Okamoto et al., 2001). Polymeric films formulated for 
controlled drug release could also decrease dose related side effects and improve 
patient compliance. Therefore, buccal films for delivery of ARVs would be ideal due to 
their numerous advantages over other buccal dosage forms. 
 
A polymer for buccal films ought to adhere easily and sufficiently to the buccal mucosa, 
must have sufficient mechanical strength, should demonstrate penetration 
enhancement and provide for controlled release of the drug. Single polymers often fail 
to demonstrate all the ideal characteristics. To overcome this problem, researchers 
have been focusing on blending polymers with similar solubilities (Abruzzo et al., 2012, 
Dubolazov et al., 2006, Juliano et al., 2008). For controlled drug release, good 
mucoadhesion and suitable mechanical strength, polymers and drugs of opposing 
solubilities may often be required. While multipolymeric multilayered films and wafers 
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have been prepared with drugs and polymers of opposing solubilities (Ding et al., 2012, 
Perugini et al., 2003), monolayered multipolymeric films (MMFs) offer more advantages 
i.e. lower production costs, improved drug release, mucoadhesivity and size (Perugini 
et al., 2003). Reports on formulation and characterization studies on MMFs with 
polymers and drugs of opposing solubilities are limited. Furthermore, the methods used 
to produce the aforementioned MMFs  require carcinogenic solvents (Perugini et al., 
2003), involve the combination of two separate mixtures under high shear rates 
(Pendekal and Tegginamat, 2012), require emulsification below room temperature 
(Perumal et al., 2008b), or need multiple solvents with additional emulsifiers (Vasantha 
et al., 2011).  
 
Didanosine (DDI) is a nucleoside reverse transcriptase inhibitor (NRTI), acts by 
competitive inhibition of HIV-1 reverse transcriptase, and can also be incorporated into 
the growing viral DNA chain to cause chain termination (Katzung et al., 2003). DDI is 
currently faced with many limitations. Rapid drug degradation of DDI in the 
gastrointestinal tract due to acid hydrolysis, together with the need for repetitive dosing, 
its short half-life, low oral bioavailability and dose-related toxicity, make DDI a suitable 
model ARV drug for incorporation into a novel buccal delivery system.  
 
DDI is currently not used as first-line therapy of HIV & AIDS due to its numerous 
limitations (Katzung et al., 2003, Rossiter, 2012). It should be noted that internationally, 
the trend is for scientists to reformulate old/disused drugs into superior delivery 
systems to improve efficacy and overcome limitations. This eliminates the high cost of 
developing new chemical entities and provides a cost effective alternative for 
optimization of drug delivery (Langer, 1990). For example, DDI is being reported as a 
drug suitable for development into novel drug delivery systems, such as enteric coated 
bioadhesive matrix tablets (Deshmukh et al., 2003), polymeric nanoparticles (Al-
Ghananeem et al., 2010), and transdermal delivery systems (Kim and Chien, 1996).  
The formulation of DDI into a buccal NDDS has not been reported in the literature, 
therefore DDI is an ideal model ARV for investigation in this study. 
 
Recent developments in the field of buccal drug delivery show an increased interest in 
nano-enabled buccal drug delivery systems. The advantages of buccal drug delivery 
can be combined with that of the nanoparticulate drug delivery systems, as discussed 
further in chapter 2. A very limited number of studies have been reported to date in this 
emerging field and antiretrovirals remain to be investigated.  
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The following important points have therefore been identified in this study: 
 
• More effective treatment strategies for HIV & AIDS are urgently required. 
• ARV drugs such as DDI currently face numerous limitations and may benefit from 
being formulated into a NDDS. 
• Although buccal drug delivery offers many advantages, formulations for this route 
have not been investigated in depth for ARVs. 
• Formulation and characterization studies on MMFs with polymers and drugs of 
opposing solubilities are limited and the preparation methods needs careful 
consideration. 
• Emerging trends indicate nano-enabled buccal films could offer more benefits 
compared to conventional films and ARVs remain to be investigated in this 
emerging field. 
 
To date, no studies have been done to establish if it is possible to design, evaluate and 
optimize the preparation of novel polymeric films for buccal delivery of DDI as a model 
ARV drug. This project therefore focused on developing a novel drug delivery system 
(controlled release polymeric films) to deliver DDI as a model ARV via an alternative 
route (transbuccal) to improve drug delivery.  
 
1.3  AIM AND OBJECTIVES OF STUDY 
 
The aim of the study was to design, evaluate and optimize the preparation of novel 
polymeric films for buccal delivery of DDI as a model ARV drug. 
 
In order to accomplish this aim, the objectives of the study were to: 
 
1. Identify optimal process and formulation variables for the preparation of 
monolayered multipolymeric films containing DDI. 
2. Evaluate the films in terms of of drug content uniformity, drug release, 
permeability, mucoadhesivity, mechanical properties and surface pH. 
3. Perform static lattice atomistic simulations (SLAS) to identify the suitability of 
the polymeric blend for buccal film formulations and to identify correlations 
between in vitro and in silico (IVIS) results. 
4. Undertake preliminary formulation studies on nano-enabled polymeric films for 
buccal delivery of ARVs. 
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1.4  SIGNIFICANCE OF THE STUDY 
 
The formulation of DDI-loaded multipolymeric mucoadhesive films offers a novel and 
promising concept for enhanced drug therapy via the buccal route. The potential 
benefits of formulating a drug delivery system proposed in this study may include the 
following: 
 
• In the absence of any antiretroviral buccal delivery systems commercially 
available in South Africa or internationally, a successful system could be of 
considerable value to HIV & AIDS patients worldwide. Cost-effective dosage 
forms could be developed that could lead to a reduction in healthcare costs in 
South Africa. 
 
• The development of this technology and polymeric system could also lend itself 
to the formulation of mucoadhesive systems for other routes (vaginal, rectal, and 
ocular), and for a wide range of disease conditions significantly affecting South 
Africa and other countries globally, e.g. diabetes, hypertension and 
communicable diseases such as tuberculosis. 
 
• The multipolymeric films proposed in this study could facilitate the loading of 
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1.5  NOVELTY OF STUDY 
 
Monolayered multipolymeric films (MMFs) with drug and polymers of opposing 
solubilities for buccal drug delivery have been formulated previously in our laboratory 
(Perumal et al., 2008b), however, the MMFs reported in this study is novel for a 
number of reasons.  
 
• Although buccal permeation studies with antiretroviral drug solutions have 
confirmed their delivery potential via this route in the literature, detailed studies 
on their subsequent formulation into a delivery system are lacking. While the 
buccal permeation properties of DDI solutions have been reported, this study is 
the first to report on its incorporation into a buccal delivery system and 
subsequent detailed characterization including essential parameters such as 
permeation from the dosage form. 
 
• While several studies on monolayered films with drugs and polymers of similar 
solubilities are reported in the literature, there are very few studies on these films 
with drugs and polymers of opposing solubilities. The advantages of the latter for 
providing multifunctional properties have been highlighted in the literature. This 
study reports for the first time on a simplified method compared to those in the 
literature for preparation of these MMFs. The method used in this study 
eliminates the need for carcinogenic or multiple solvents and emulsifiers, can be 
done at room temperature, and does not require special equipment such as a 
homogenizer. In addition, detailed physico-mechanical evaluations, essential for 
optimisation of these MMFs, are lacking in the current literature.  
 
• To the best of my knowledge, this is the first time that molecular modelling on 
buccal polymeric film formulations has been done to identify the mechanism of 
interaction between these two polymers (EUD & HPMC) and their suitability for 
combined use. This led to a mechanistic understanding of film formation as well 
as mucoadhesivity and drug release properties.  
 
• This study reports on the first nano-enabled buccal MMF using SLNs for delivery 
of an ARV. This technology may serve as a platform for developing future nano-
enabled buccal MMFs for other antiretrovirals as well as other disease conditions. 
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1.6  OVERVIEW OF DISSERTATION 
 
Chapter 1 provides an introduction and summarizes the background to the study. It 
outlines the challenges encountered with current antiretroviral therapy and buccal drug 
delivery systems and explores the rationale for and novelty of the study. It also covers 
the aim and objectives of the study.  
 
Chapter 2 is a literature review, focusing on HIV & AIDS drug therapy and strategies to 
address its current limitations. The chapter particularly focuses on buccal drug delivery 
and polymeric films as a drug delivery strategy. An overview of buccal drug delivery is 
presented and different types of buccal drug delivery systems are outlined. 
Furthermore, various preparation methods and characterization techniques of buccal 
polymeric films are elucidated before highlighting emerging work in the field of nano-
enabled buccal drug delivery. Finally, DDI as a model ARV is elaborated upon. 
 
Chapter 3 (publication) is a first-author article reporting on novel work published in an 
ISI international journal. The chapter is presented in the required format of the journal 
and is the final revised accepted version. It describes the development of novel 
monolayered multipolymeric buccal films with drug and polymers of opposing 
solubilities using DDI as model ARV drug.  
 
Chapter 4 (manuscript) is a first-author manuscript submitted to an ISI international 
journal. The chapter is presented in the required format of the journal and is the final 
version submitted for review. It explores the use of nano-enabled polymeric films. More 
specifically, it summarizes work done using solid lipid nanoparticles entrapped into 
films for buccal delivery of DDI.  
 
Chapter 5 describes the conclusions and future recommendations from the study to 
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CHAPTER TWO 
HIV & AIDS AND BUCCAL DRUG DELIVERY 
 
2.1  INTRODUCTION 
 
This chapter presents a review of the literature of the theoretical concepts on HIV & 
AIDS and buccal drug delivery. The chapter focuses on HIV & AIDS drug therapy and 
strategies to address its current limitations. An overview of buccal drug delivery is 
presented and different types of buccal drug delivery systems are outlined. 
Furthermore, various preparation methods and characterization techniques of buccal 
polymeric films are elucidated, before highlighting emerging work in the field of nano-
enabled buccal drug delivery. Finally, didanosine as a model ARV is elaborated upon. 
 
2.2  INTRODUCTION TO HIV & AIDS  
 
Human Immunodeficiency Virus (HIV) infection and Acquired Immune Deficiency 
Syndrome (AIDS), commonly referred to as HIV & AIDS, have remained one of the 
leading causes of death worldwide, and is a major cause of mortality in sub-Saharan 
Africa (Merson et al., 2008, WHO, 2013). While antiretrovirals (ARVs) have proven to 
be useful in the treatment and management of HIV & AIDS, several disadvantages 
currently exist with respect to drug therapy (Carpenter et al., 2000). 
 
According to estimates from the UNAIDS (2012) Report on the Global AIDS Epidemic, 
approximately 34 million people worldwide were living with HIV by the end of 2011, 2.5 
million new infections and 1.7 million AIDS-related deaths were reported in 2011 alone. 
When compared to global statistics, sub-Saharan Africa is the most affected region, 
with nearly one in every 20 adults living with HIV. More than two-thirds (69 %) of all 
people worldwide who are infected with HIV live in sub-Saharan Africa. It is estimated 
that more than 90% of all children newly infected with HIV in 2011 live in sub-Saharan 
Africa (UNAIDS, 2012). Despite the increased global and local interventions, such as 
patient counselling, increased awareness, education and improved drug supply, much 
remains to be accomplished, as the number of new infections remains 
disproportionately high. HIV is most commonly transmitted via vaginal or anal sexual 
intercourse. Other possible means of infection include sharing of contaminated needles 
among drug users, transfusion of contaminated blood products and transmission from 
mother-to-child during pregnancy, labour or breastfeeding (das Neves et al., 2010). 
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From the two known species of HIV, HIV-1 is globally more prevalent than HIV-2 
(Lever, 2009). HIV-2 is associated with slower progression to immunodeficiency and is 
more prevalent in West Africa (das Neves et al., 2010). HIV is a retrovirus known for its 
ability to use its reverse transcriptase enzyme to convert the ribonucleic acid (RNA) 
genome to double-stranded deoxyribonucleic acid (DNA). The DNA is then integrated 
into the chromosomes of the infected host cells where it is termed a provirus (Lever, 
2009). The structure of the HIV viron is shown in Figure 2.1. The viral genome contains 
three structural genes i.e. gag, pol and env. Respectively, these genes code for 
important antigens (gag gene); viral enzymes such as reverse transcriptase, integrase 
& protease (pol gene), gp120 and gp41 glycoproteins, responsible for recognizing the 
CD4+ receptor and the CCR5 or CXCR4 chemokine receptors of the host cell 
membrane; and for virus/cell fusion (env gene) (das Neves et al., 2010, Lever and 
Jeang, 2006, Lever, 2009). The virus mostly infects T-helper lymphocytes (CD4+) but 
may also infect macrophages.  The defining characteristic of AIDS is the depletion of 
CD4+ cells (T-helper lymphocytes). The ensuing immunosuppression may result in 
opportunistic infections such as Mycobacterium tuberculosis (Stoddart and Reyes, 
2006).  
 
An understanding of the processes involved in the HIV lifecycle is important for 
















Figure 2.1: Structure of HIV viron (MBBS Medicine (Humanity First), 2013). 
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2.3  HIV & AIDS DRUG THERAPY AND ITS CURRENT LIMITATIONS 
 
The goal of treating an established HIV infection with antiretroviral therapy is to achieve 
durable suppression of viral replication (i.e. an undetectable viral load). This is 
generally achieved using a combination of three or more antiretrovirals, known as 
highly active antiretroviral therapy (HAART) (Rossiter, 2012). Presently, there are five 
major classes of antiretroviral drugs used to treat people infected with HIV, namely 
reverse transcriptase inhibitors, protease inhibitors, fusion inhibitors, integrase 
inhibitors and more recently, CCR5 antagonists which is also known as entry inhibitors. 





Figure 2.2: Sites of drug action during HIV lifecycle (University of Arizona, 2013). 
 
The currently available drugs suppress the virus, even to undetectable levels. Hence, 
people with HIV need to continuously take antiretroviral drugs (National Institute of 
Allergy and Infectious Diseases, 2013). Antiretrovirals may be used to prevent infection 
following accidental exposure, to prevent transmission from mother to child, or to treat 
established HIV infection. The goal of treating established HIV infection is to achieve 
durable suppression of viral replication. As HIV reproduces itself, variants of the virus 
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emerge, including some that are resistant to antiretroviral drugs. Therefore, guidelines 
recommend that people infected with HIV take a combination of antiretroviral drugs 
known as HAART. This strategy, which typically combines drugs from at least two 
different classes of antiretroviral drugs, has been shown to effectively suppress the 
virus when used properly. HAART has revolutionised how people infected with HIV are 
treated, and works by suppressing the virus and decreasing the rate of opportunistic 
infections (National Institute of Allergy and Infectious Diseases, 2013). 
 
Fixed-dose combination tablets have emerged in an effort to facilitate combining two or 
more ARV drugs of a HAART regimen, and to improve patient compliance by reducing 
the total daily pill burden (Zolopa, 2010). However, fixed-dose combinations should not 
be prescribed for patients requiring dose adjustments, such as in the case of hepatic or 
renal impairment or in young children. The fixed dose combination containing 
emtricitabine (FTC), tenofovir (TDF) and efavirenz (EFV), which is a single pill on a 
once-a-day regimen marketed as Atripla, and has been welcomed as an expanded 
effort to combat the HIV & AIDS crisis (Zolopa, 2010). 
 
Drugs currently available for the treatment of HIV & AIDS vary significantly in their 
pharmacokinetic properties, as highlighted in Table 2.1. The ARVs with low oral 
bioavailability and a short half-life are set to benefit from being reformulated into novel 
drug delivery systems. Although more than twenty ARVs have been approved for 
treating HIV, a need still exists to develop new chemical entities, due to ever increasing 
drug resistance and unavoidable side effects. Among the newer drugs under 
investigation are PRO 140 (EI), TNX-355 (EI), BMS-663068 (EI), Cenicriviroc (EI), 
Dolutegravir (II), Lersivirine (NNRTI), KP-1461 (NRTI), Elvucitabine (NRTI), Racivir 
(NRTI) and Festinavir (NRTI) undergoing phase II clinical trials at the Food and Drug 
Administration (FDA) in the USA. Elvitegravir (II) and Apricitabine (NRTI) are showing 
promising results in phase III trials. Vivecon is currently the only candidate in a 
potentially new class of ARVs called maturation inhibitors, and is undergoing phase III 
clinical trials (Avert, 2013).  
 
Although ARV drug therapy has contributed significantly to improved disease 
management, annual mortality rates due to HIV & AIDS are still alarmingly high, with 
approximately two million deaths reported globally. Of concern is that as recently as the 
end of 2011, nearly seven million people eligible for HIV treatment still did not have 
access to suitable and affordable drug therapy (UNAIDS, 2012). 
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Whilst ARVs have proven to be useful in the treatment and management of HIV & 
AIDS, several disadvantages and limitations currently exists. Many of the ARVs 
undergo extensive first pass hepatic metabolism and gastrointestinal degradation, 
which leads to reduced bioavailability (Table 2.1). The short half-lives of several ARVs 
(Table 2.1) necessitates frequent administration of doses, thereby leading to reduced 
patient compliance (Li and Chan, 1999). 
 
There are concerns regarding adverse effects associated with long-term usage of 
HAART, such as HIV associated lipodystrophy, central adiposity, dyslipidaemia, 
hyperlipidaemia, hyperglycaemia and insulin resistance (Behrens et al., 2000, 
Vigouroux et al., 1999).  The major contributing factor to ARV related side effects can 
be attributed to the inadequate drug concentrations reaching the site of action, and the 
low bioavailability of several ARV drugs, necessitating the use of large doses to 
achieve a therapeutic effect. Many of the currently available tablet formulations (Table 
2.1) are very large and pose swallowing difficulties, especially for geriatric and 
paediatric patients. High doses, complex HAART dosing regimens, physical size 
limitations and side effects from multiple drugs all contribute to reduced patient 
compliance (Chandwani et al., 2012).  
 
Poor drug solubility and limited membrane permeability also pose formulation 
difficulties (Sharma and Garg, 2010). HIV, being localised to inaccessible 
compartments in the human body, such as the lymphatic system, central nervous 
system and within macrophages, results in yet another treatment challenge. 
Therapeutic drug concentrations cannot be achieved in these compartments by the 
majority of ARVs, and the necessary plasma drug concentrations fail to be maintained 
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Table 2.1:  Available ARV drugs, their classes, dosage forms and pharmacokinetic 
properties. 





Nucleoside/Nucleotide reverse transcriptase inhibitors (NRTI) 
Zidovudine (AZT) 1.1 0.5-1.5 60 Capsule, tablet, syrup, injection 
Lamivudine (3TC) 3-6 0.9 86 Tablet, oral solution 
Emtricitabine (FTC) 10 1-2 93 Tablet 
Abacavir (ABC) 1-2 1-1.5 83-100 Tablet, oral solution 
Tenofovir DF (TDF) 17 1-2 25-39 Tablet 
Didanosine (DDI) 1.3-1.6 0.6-1 30-40 Tablet, capsule (EC), powder for reconstitution 
Stavudine (D4T) 1-1.6 0.5-0.75 80 Capsule, powder for reconstitution 
*Zalcitabine (DDC) 1-3 0.8-1.5 85 Tablet 
Non-nucleoside reverse transcriptase inhibitors (NNRTI) 
Rilpivirine (RPV) 50 4-5 Unknown Tablet 
Etravirine (ETR) 30-40 2.5-4 Unknown Tablet 
Delavirdine (DLV) 5.8 1.2 85 Tablet 
Efavirenz (EFV) 40-50 5 42-80 Tablet, capsule 
Nevirapine (NVP) 25-30 1.5 >90 Tablet, suspension 
Protease Inhibitors (PI) 
Tipranavir (TPV) 6 3 No data Capsule, oral solution 
Indinavir (IDV) 1.2 0.8 65 Capsule 
Saquinavir (SQV) 1.5-2 > 1 fasting,  3 with food Erratic, 4 Tablet, capsule 
Lopinavir/ritonavir (LPV/r) 5-6 (LPV) No data No data Tablet, oral solution 
**Amprenavir 7-10 1-2 No data Liquid-filled capsule 
***Fosamprenavir (FPV) 7.7 1.5-4 No data Tablet, suspension 
Ritonavir (RTV) 3-5 3.4 65 Tablet, capsule, oral solution 
Darunavir (DRV) 15 2.5-4 37 Tablet, suspension 
Atazanavir (ATV) 7 2.5 No data Capsules 
Nelfinavir (NFV) 3.5-5 3.4-4 20-80 Tablet, oral powder 
Fusion & Entry Inhibitors (FI & EI) 
Enfuvirtide (ENF) 3.8 8 84 Injection 
Maraviroc 14-18 No data 23-33 Tablets 
Integrase Inhibitors (II) 
Raltegravir 9 3 No data Tablet 
*Zalcitabine was discontinued in 2006. **Amprenavir was discontinued in 2004; a prodrug version 
(***fosamprenavir) is currently available. Data obtained from: (Ojewole et al., 2008, Li and Chan, 1999, 
Rossiter, 2012, drugs.com, 2013)  
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2.4  STRATEGIES TO ADDRESS LIMITATIONS OF ARV DRUGS 
 
The identification of new drugs and chemical modification of existing ARV drugs 
(Hartman and Buckheit, 2012), the design and development of novel drug delivery 
systems (Benghuzzi, 2000, Dutta et al., 2007, Saravanakumar et al., 2010) and 
investigation of alternative routes to deliver ARVs (Carvalho et al., 2013, Patel et al., 
2012, Rambharose et al., 2013) are being explored to overcome the current limitations 
associated with ARV therapy. Novel drug delivery systems (NDDS) have been 
identified as a useful tool by formulation scientists to enhance drug delivery, and have 
contributed significantly in the past decade to augment various classes of drugs 
including ARVs. Table 2.2 provides a summary of some of the formulation studies 
exploring NDDS for delivery of ARVs.  
 
The rationale for developing these NDDS clearly shows that formulation modification 
serves as an effective strategy to overcome current limitations. It can also be seen from 
Table 2.2 that a wide range of ARVs have been receiving increased attention, 
specifically in the last decade. For these ARVs, numerous NDDS have been explored 
to overcome the specific ARV’s limitations. Examples of novel drug delivery systems 
that have been explored include sustained release matrix tablets (Sánchez-Lafuente et 
al., 2002b) ceramic implants (Benghuzzi, 2000), liposomes (Dubey et al., 2010) and 
nanoparticles (Kuo and Chung, 2011b). 
 
Along with developing NDDS for ARVs, researchers have also explored various 
alternate routes to improve drug delivery of ARVs other than the conventional oral 
route. Alternate routes for delivery under investigation include: transdermal (Gerber et 
al., 2008), nasal (Carvalho et al., 2013), vaginal (Johnson et al., 2010) and buccal 
delivery (Ojewole et al., 2012, Xiang et al., 2002). Table 2.3 provides an extensive 
summary of formulation studies exploring alternate routes for delivery of ARVs. The 
rationale for selecting the route, as well as different formulations and ARVs being 
investigated per route are summarized. It can be seen that the focus to date has been 
mainly on the delivery of single ARVs via these routes. More research into multi-ARV 
delivery systems is required. From Table 2.3 it can also be seen that the majority of 
studies have been focusing on the transdermal and nasal routes of administration of 
ARVs. This may be due to the higher levels of patient compliance associated with 
these routes. Conversely, the rectal route appears to have received no attention in 
recent studies, possibly due to poor patient compliance associated with this route.  
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Many ARVs have been delivered via alternate routes, with zidovudine having received 
the most interest and being investigated for delivery via all the alternative routes.  
 
For the buccal route, studies are limited compared to the transdermal route, and have 
focused mostly on permeability studies with ARV drug solutions rather than formulation 
studies. To date, studies reporting on the delivery of ARVs via the buccal route remain 
limited. The majority of work thus far has focussed on in vitro drug permeability studies 
using only drug solutions of zalcitabine (Shojaei et al., 1999, Xiang et al., 2002), 
didanosine (Ojewole et al., 2012, Rambharose et al., 2013) and tenofovir (Rambharose 
et al., 2013). The only available published paper on buccal polymeric dosage forms 
containing ARVs is of zidovudine polymeric patches recently produced by Reddy et al. 
(2012). Characterization studies were limited and did not include critical parameters 
such as in vitro permeation or mechanical properties. ARV buccal drug delivery 
systems have not been comprehensively investigated or characterised, and a clear 
need exists for formulation optimization in this field. This study focused on the 
development of a NDDS for delivery of an ARV via the buccal route. The following 
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Table 2.2:  Summary of formulation studies exploring novel drug delivery systems 
(NDDS) for delivery of ARVs. 





Enteric-coating prevents acid-induced 
degradation of didanosine, whilst sustained-
release and bioadhesive properties may further 
improve the drug’s low oral bioavailability. 






Once daily, sustained release formulations 
reduce the frequency of administration and 
improve patient compliance. 
Saravanakumar 
et al. (2010) 
Suspensions Indinavir 
Subcutaneously administered lipid–drug 
complexes in suspension form can accumulate 
in lymph nodes at much higher levels than the 
soluble form of the drug where HIV localizes. 




Improve the drugs low oral bioavaibility and 
provide sustained action through continuously 
releasing the drug. 




The sustained delivery of AZT from ceramic 
implantable capsules could be achieved and oral 






Penetration-enhancing quality of ethanol is well 
known. Ethanolic liposomes can transport drugs 
more effectively through the stratum corneum 
into the deeper layers of the skin than 
conventional liposomes. 




Saquinavir is lipophilic, poorly water-soluble and 
undergoes extensive first-pass metabolism. By 
formulating it as a lipid formulation that targets 
intestinal lymphatic transport, oral bioavailability 




Niosomes offers greater stability than liposomes 
and are more cost-effective. Colloidal drug 
carrier system would be cleared by the 
mononuclear phagocytes system where HIV 
localizes. No pediatric liquid formulation of 
tenofovir is available. 




Liquid pediatric formulation of EFV not available. 
Polymeric micelles would improve the aqueous 
solubility and the oral bioavailability of the drug. 
Chiappetta et al. 
(2009) 
Dendrimers Efavirenz 
Due to their highly branched, synthetic, 
monodispersed nature they can be useful for 
targeted drug delivery of ARVs. 
Dutta et al. 
(2007) 
Nanopowders Saquinavir 
The dissolution rates of poorly soluble drugs can 
be enhanced by milling thereby increasing GIT 
absorption and/or membrane permeation. 
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Table 2.3:  Summary of formulation studies exploring alternate routes for delivery of 
ARVs. 
Route of 
Administration Formulation Antiretroviral Reference 
Rationale of Route 
Selected 
Transdermal 
Suspension Zidovudine Jin et al. (2000) 
Drugs exhibit dose 
dependent toxic side 
effects. Controlled drug 
delivery systems are 
preferred for long-term 
treatment of HIV/AIDS. 
Noninvasive zero-order 
delivery via the 
transdermal route would 
be desirable. 
Liposomes Lamivudine Pai and Devi (2009) 
Pheroid™ Stavudine Holmes et al. (2010) 
Alcoholic solutions Zalcitabine Kim and Chien (1995) 
Gel Zidovudine Pokharkar et al. (2010) 






Avoidance of hepatic 
first pass metabolism 




Solution Didanosine* Wintergerst et al. (1999) 






Johnson et al. 
(2010) 
Anti-HIV microbicide 
can block transmission 
of HIV at the vaginal 
mucosal epithelium. 
This route is not used to 





Zidovudine Ndesendo et al. (2011) 
Gel Tenofovir Abdool Karim et al. (2010) 
Nasal 
Suspension Zidovudine Seki et al. (1994) 
Allows for painless, 
minimally invasive, self-
administration of drugs 
and can also bypass the 
blood–brain barrier 
when used together 
with nanoparticles. 
Avoiding first-pass 
metabolism and oral 
administration side 
effects. Rapid 
absorption can be 
achieved due to the 
highly vascularized 
nature. 
Micelles Efavirenz Chiappetta et al. (2013) 
Liquid crystal 
precursor Zidovudine 









et al. (2010) 
Buccal 
Solution Didanosine Ojewole et al. (2012) 
Bypasses hepatic first 
pass metabolism and 
GIT degradation, 
resulting in increased 
drug bioavailability. It 
has higher permeability 
the skin, has a relatively 
large surface area and 
good accessibility. 
Solution Zalcitabine Xiang et al. (2002) 
Solutions Tenofovir or Didanosine 
Rambharose et 
al. (2013) 
Patches Zidovudine Reddy et al. (2012) 





       23 
 
Literature Review: HIV & AIDS and Buccal Drug Delivery Chapter Two 
 
2.5  BUCCAL DRUG DELIVERY 
 
Drug delivery via the buccal route has recently received increased interest in the 
literature as an alternative to oral and other conventional routes of administration, due 
to its numerous advantages over these routes. A number of reviews have been 
published on the structure of the oral cavity (Squier and Kremer, 2001), mucoadhesion 
mechanisms (Smart, 2005a), drug delivery via the buccal route (Patel et al., 2011, 
Shojaei, 1998, Hoogstraate and Wertz, 1998), buccal dosage forms (Sudhakar et al., 
2006, Nair et al., 2013, Madhav et al., 2009, Morales and McConville, 2011) and buccal 
permeation enhancement (Şenel and Hıncal, 2001, Nicolazzo et al., 2005, Hassan et 
al., 2010).  This section therefore serves only as an overview of the relevant elements 
essential to this study. 
 
2.5.1  Overview of the Oral Mucosa 
 
The oral cavity is lined with the oral mucosa, and includes the buccal, sublingual, 
gingival and palatal mucosa. The uppermost layers of the oral mucosa are comprised 
of closely compacted epithelial cells (Figure 2.3) the function of which is to protect the 
underlying tissues from damage and fluid loss (Patel et al., 2011). Below the epithelial 
layer are the basement membrane, lamina propria and submucosa. This epithelium is 
comparable to stratified squamous epithelium found in other areas of the body. It has a 
mitotically active basal cell layer (basement membrane) (Figure 2.3) that gives rise to a 
number of intermediate differentiating cell layers, with the outermost layers being 
sloughed off (Haas and Lehr, 2002). The buccal mucosal epithelium consist of 
approximately 40–50 cell layers, whereas the sublingual epithelium consist of 
comparatively fewer layers (Madhav et al., 2009).  
 
Figure 2.3: Schematic representation of buccal mucosa (Smart, 2005b). 
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There are three categories of drug delivery within the oral cavity (i.e. sublingual, buccal 
and localized drug delivery). Selecting one over another is mainly based on anatomical 
and permeability differences that exist among the various oral mucosal sites (Xiang et 
al., 2002). The buccal and sublingual mucosa is non-keratinized with relatively good 
permeability (Table 2.4), making them potential candidates for systemic delivery of 
drugs via an alternate route. As the main aim of this study was the preparation of novel 
polymeric films for buccal delivery of didanosine, this route would be reviewed in depth.  
 
Table 2.4: Characteristics of the oral mucosal delivery sites. 







Permeability Residence Time 
Blood 
Flow* 
Buccal NK 500-600 5-7 50.2 ± 2.9 Intermediate Intermediate 20.3 
Sublingual NK 100-200 20 26.5 ± 4.2 Very good Poor 12.2 
Gingival K 200 - - Poor Intermediate 19.5 
Palatal K 250 24 20.1 ± 1.9 Poor Very good 7.0 
Adapted from (Patel et al., 2011) [NK = non-keratinized, K = Keratinized, * In rhesus monkeys (mL/min/100g tissue)] 
 
Buccal transportation mainly occurs via passive diffusion across lipid membranes, 
either through paracellular or transcellular pathways (Figure 2.4). This makes buccal 
drug delivery suitable for transporting both hydrophilic and lipophilic drugs (Patel et al., 
2011). Hydrophilic drugs would be limited to the hydrophilic regions of the paracellular 
spaces and cytoplasm. Likewise, lipophilic drugs would favour penetration through the 
lipophilic cell membrane of one cell directly into the next until the systemic circulation is 
reached (Shojaei, 1998). While a drug can make use of both pathways simultaneously, 











Figure 2.4: Schematic representation of different routes of drug permeation.  
        Adapted from (Patel et al., 2011). 
       25 
 
Literature Review: HIV & AIDS and Buccal Drug Delivery Chapter Two 
 
2.5.2  Advantages of Drug Delivery via the Oral Mucosa 
 
Drug delivery via the buccal route can be considered as a favourable alternative to oral 
and other conventional routes of administration for the following reasons: 
 
• Drugs that are absorbed through the buccal mucosa directly enter the systemic 
circulation, bypassing the gastrointestinal tract and first-pass metabolism in the 
liver leading to improved bioavailability (Madhav et al., 2009). 
• The buccal mucosa is relatively permeable and robust in comparison to other 
mucosal tissues (Patel et al., 2011). 
• The buccal mucosa has a smooth and relatively immobile surface, which is easily 
accessible, and makes self-application and removal of the delivery system easy 
(Madhav et al., 2009). 
• The permeability of the buccal mucosa is higher than that of skin (Squier and 
Hall, 1985). Hence, a lower loading dose in a buccal device could provide the 
same therapeutic effect as a transdermal patch. 
• Buccal delivery is also a potential attractive delivery system for pediatrics as well 
as for patients with swallowing difficulties. 
• The advantages of a buccal delivery system can further be increased by 
formulating the drug into a controlled release dosage form. This will lead to a 
reduction of dose related side effects and improved patient compliance. 
 
2.5.3  Disadvantages of Drug Delivery via the Oral Mucosa 
 
There are some disadvantages of using the buccal route for drug delivery, which 
includes low mucosal permeability of certain drugs, a continuous secretion of saliva 
leading to dilution of drug and the need for formulation approaches to promote 
retention on the mucosae (Patel et al., 2011). Nonetheless, the distinct advantages 
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2.5.4  Candidate Drugs and Disease States 
 
Buccal mucoadhesive dosage forms have been developed for numerous types of drugs 
and disease conditions. Drugs with short half-lives requiring prolonged effects, or 
having low membrane permeability, with sensitivity to enzymatic or acidic degradation 
in the GIT and poor solubility may be successfully delivered via mucoadhesive oral 
delivery systems (Ahuja et al., 1997). 
 
Treatment of systemic disease conditions in addition to local oral diseases may be 
achieved using buccal drug administration. Fluconazole (Yehia et al., 2009) and 
metronizazole (El-Kamel et al., 2007) are a few of the drugs being investigated for 
enhanced local effects by incorporating them into mucoadhesive buccal dosage forms. 
Drugs that undergo gastrointestinal degradation may benefit from buccal delivery. 
Several peptides, including insulin (Giovino et al., 2012) and lysozyme (Morales et al., 
2013), have been reported to successfully be delivered via the buccal route, thereby 
avoiding their GIT degradation. 
 
Drugs such as propranolol (Abruzzo et al., 2012) and carvedilol (Rana and Murthy, 
2013), which are used in hypertension, undergo significant first past metabolism and 
may benefit considerably from being delivered via this route. Examples of other drugs 
and disease states potentially benefitting from being delivered bucally include: 
salbutamol sulphate used in asthma (Vasantha et al., 2011), glibenclamide for diabetes 
mellitus (Muzib and Kumari, 2011), griseofulvin (Meng et al., 2011) as systemic 
antimicrobial and ARVs such as zalcitabine (Xiang et al., 2002) or didanosine (Ojewole 
et al., 2012) for HIV & AIDS treatment. Thus, both non-communicable and 
communicable diseases may benefit from using this route of drug administration.  
 
2.5.5  Development of Buccal Dosage Forms 
 
Several conventional and novel buccal dosage forms have been developed in the past 
two decades. They include solutions (Ungphaiboon and Maitani, 2001), sprays, 
ointments (Petelin et al., 2004), gels (Martin et al., 2003), lozenges (Codd and Deasy, 
1998), tablets (Boyapally et al., 2010, Cappello et al., 2006), powders, chewing gums, 
patches (Cavallari et al., 2013, Perioli et al., 2004), wafers (Ayensu et al., 2012a) and 
films (Abruzzo et al., 2012, El-Kamel et al., 2007, Prodduturi et al., 2005). They are 
categorized into three types namely: liquid, semi-solid or solid formulations (Sudhakar 
et al., 2006).  
       27 
 
Literature Review: HIV & AIDS and Buccal Drug Delivery Chapter Two 
 
Solid buccal formulations, such as tablets and lozenges, are produced commercially 
more often than liquids, semi-solids or even buccal films. Only a few buccal films or 
patches have successfully entered the pharmaceutical market, with most being 
designed to release drugs rapidly in order to produce a fast onset of action. A prime 
example is fentanyl buccal films, marketed as Onsolis® used in cancer breakthrough 
pain management (Twycross et al., 2012). Limitations associated with buccal films, 
including uncontrolled swallowing of released drug and difficulties maintaining the film 
at the absorption site, prevent it from being used more widely (Patel et al., 2011). More 
research is required to address these limitations, especially by using mucoadhesive 
systems, before more buccal films become commercially viable.  
 
2.5.6  Characteristics of a Buccal Delivery System 
 
It is important to take cognizance of the desired characteristics required during the 
development of a novel drug delivery system. Important factors to consider when 
developing a buccal drug delivery system therefore include the following (Hearnden et 
al., 2012): 
 
• Disturbances to taste and speech will decrease patient acceptability. Films 
should be thin, flexible and smooth. 
• Self-administration of films should be easy to apply and remove if adverse 
effects occur. 
• The drug release and penetration across the oral mucosa's epithelium are 
critical factors. Controlled delivery may be advantageous to avoid repeated 
administration of doses especially in chronic conditions. 
• The nature of the drug is vital. Lipophilic, non-ionised species and low molecular 
weight substances are best suited for buccal delivery.  
 
2.5.7  Types of Buccal Delivery Systems 
 
Numerous types of buccal delivery systems  currently exists, with a majority of studies 
focussing on buccal mucoadhesive tablets, ointments, gels, patches, wafers and films 
(Hearnden et al., 2012, Madhav et al., 2009, Morales and McConville, 2011, Patel et 
al., 2011, Sudhakar et al., 2006).  
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2.5.7.1  Buccal Mucoadhesive Tablets 
 
Tablets utilise the whole absorptive surface of the oral cavity after the drug is dissolved 
in the saliva. The use of conventional solid preparations, such as tablets and lozenges 
are restricted due to variability in saliva production and sucking intensity, accidental 
swallowing of the system and relatively short exposure times (Madhav et al., 2009). To 
overcome these limitations, research has been focussing on developing a range of 
mucoadhesive tablet formulations (Figure 2.5) (Boyapally et al., 2010, Cappello et al., 
2006, Şenel et al., 1998, Taylan et al., 1996). These tablets are superior, as they 
adhere to the mucosa, thereby increasing exposure time and drug absorption. 
 
Buccal tablets are prepared by compressing powder mixes that can dissolve or adhere, 
depending on the type of excipients used. Simple matrix tablets (Figure 2.5a), 
composed of drug and bioadhesive polymers, produce multidirectional drug release 
into the oral cavity. Alternatively, a water impermeable backing layer can be 
incorporated (Figure 2.5b,c,f) to ensure unidirectional drug release. Formulation 
incompatibilities or additional requirements for controlled drug delivery might 
necessitate the use of other inert excipients (Figure 2.5e) or a non-bioadhesive 
controlled release matrix (Figure 2.5d,f) (Patel et al., 2011, Rossi et al., 2005). 
 
Major limitations associated with the use of buccal tablets include their physical size 
and thickness, which would influence patient acceptability should it cause irritation. 
Children and the elderly are more prone to possible discomfort, and a possibility exist 











Figure 2.5:  Schematic representation of different types of matrix tablets intended for 
buccal drug delivery. Adapted from (Rossi et al., 2005).  
Key:  
Arrows: Direction of drug release. 
Blue: Water impermeable backing, 
Green: Non-bioadhesive controlled    
release matrix,  
Orange: Bioadhesive matrix, 
Purple: Inert excipient,  
Mottled: With drug. 
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2.5.7.2  Ointments and Gels 
 
Semi-solid oral dosage forms, including ointments and gels, are applied topically onto 
the oral mucosa surface, and can be used to achieve either local or systemic effects. 
They are formulated to contain a polymer(s), the drug and other required excipients, 
either dissolved or suspended as a fine powder in a suitable base. Hydrogels are 
produced using polymers, which are hydrated in an aqueous environment without 
dissolving. They act as a controlled release drug delivery system by physically 
entrapping drug molecules, which are slowly released by diffusion or erosion after gel 
hydration (Martin et al., 2003). Bioadhesive polymers can be incorporated to prolong 
the adherence to mucosal surfaces or modulate the rate of drug release (Sudhakar et 
al., 2006). Semi-solid preparations are applied using a finger or applicator to the target 
region, and have higher patient acceptability in terms of mouth feel compared to solid 
dosage forms (Patel et al., 2011). Other advantages include the intimate contact being 
attained with the mucosal membrane and the rapid drug release at the absorption site. 
Gels may not deliver an accurately measured dose of drug in comparison with a unit 
dosage form (Squier and Kremer, 2001), making them less suitable for drugs, with a 
narrow therapeutic window. Another shortcoming of semi-solid buccal preparations is 
the poor retention at the site of application, requiring the incorporation of a bioadhesive 
polymer (Patel et al., 2011). 
 
2.5.7.3  Powders 
 
Limited work has been reported on powders intended for administration into the oral 
cavity. Powders prepared as bioadhesive microparticles allow for intimate contact with 
the oral mucosa as a result of their unique physical properties. Due to their  reduced 
size, they are less likely to cause local irritation at the site of adhesion compared to 
buccal tablets (Sudhakar et al., 2006). 
 
2.5.7.4  Solutions and Sprays 
 
Liquid dosage forms include solutions, suspensions and sprays, which are produced by 
dissolving or suspending the drug in a suitable vehicle. Their use is predominantly 
aimed at exerting local action in the oral cavity. Several commercially available 
antimicrobial preparations are available (Hearnden et al., 2012) containing actives such 
as chlorhexidine gluconate. Major drawbacks associated with such liquid dosage forms 
are that they have reduced retention times and precise dosing of drugs are difficult to 
achieve (Smart, 2005b). 
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2.5.7.5  Patches, Wafers and Films 
 
Patches, wafers and films are solid dosage forms intended for drug administration into 
the oral cavity. They can be used to achieve localized or systemic effects. Patches and 
films are most often prepared by casting a solution of the polymer, drug and other 
required excipients onto a substrate and allowing it to dry. The size of the patches can 
vary (≤ 10-15 cm2), but are most frequently 1-3 cm2 (Smart, 2005b). Similar to buccal 
tablets, patches can also be prepared for multidirectional or unidirectional drug release 
by incorporating an impermeable backing layer (Patel et al., 2011). Wafers are thin 
strips of polymeric films, containing up to 20 mg of drug, which dissolves rapidly on the 
tongue in less than 30 seconds. Wafers deliver drugs (which are able to cross the 
permeability barrier) directly into the blood supply for quick treatment of conditions such 
as migraines, pain relief and nausea (Hearnden et al., 2012).  
 
Films, patches and wafers share many of the advantages and disadvantages of buccal 
tablets, but by being thin and flexible, they cause less irritation and therefore will have 
higher patient acceptability. A drawback is the relative thinness of the films, which may 
result in overhydration and loss of the adhesive properties (Squier and Kremer, 2001). 
This can however be overcome by the incorporation of appropriate mucoadhesive 
polymers. Current literature indicates that research is more focused towards 
mucoadhesive films and patches. Inclusion of various mucoadhesive agents can be 
used to extend the residence time of dosage forms at the site of application and 
facilitate drug absorption (Patel et al., 2011).  
 
Table 2.5 shows a summary of several drugs investigated for buccal films in the 
literature. The main excipients used, preparation methods and characterizations were 
extracted from these papers and are presented. It can be clearly seen that buccal films 
are being investigated for various classes of drugs, confirming its wide applicability. In 
addition, although excipients vary from study to study, the most common method of film 
preparation remains the casting and solvent evaporation technique. Characterization 
methods have advanced over the last few years and have evolved from simple drug 
release studies to detailed characterization of all relevant aspects involved in 
formulation development. Similarly to the other NDDS summarised in Table 2.2 and 
Table 2.3, it can be clearly seen from Table 2.5 that studies into buccal polymeric films 
have mainly been limited to incorporation of single drugs. Clearly, the possibility to 
deliver multiple drugs exists and researchers should focus on this in the future.
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Table 2.5:  Summary of investigated buccal films. 
Active 
Ingredients Main Excipients 
Preparation 







In vitro permeation, dissolution studies, 
DSC. 
Okamoto et 

















Drug content, morphology (SEM), 
swelling, film degradation (3 months),  






cellulose Na+ salt 
Casting/solvent 
evaporation 
Swelling, erosion, mucoadhesion, 
organoleptic characteristics, in vitro drug 
release, in vivo drug release. 
Perioli et al. 
(2004) 
Clotrimazole Poly(ethylene oxide) Hot-melt extrusion 
Drug content, bioadhesion, DSC, TGA, 
mechanical properties, in vitro drug 
release, stability studies, XRD. 
Prodduturi et 
al. (2005) 
Lidocaine Hydroxypropyl cellulose, HPMC 
Hot-melt 
extrusion 
Drug content, bioadhesion, dissolution 
studies DSC, wide angle XRD. 








In vitro drug release,  








in various ratios 
Casting/solvent 
evaporation 
FTIR, swelling, mucoadhesion, tensile 
strength, in vitro drug release. 
Kim et al. 
(2007) 
Chlorhexidine Sodium alginate, HPMC, chitosan 
Casting/solvent 
evaporation 
Drug content, film morphology, in vitro 
drug release, swelling,  
preliminary in vivo studies. 
Juliano et al. 
(2008) 
Drug Free Silk-fibroin, HPMC, PEG 400 
Casting/solvent 
evaporation 
Thickness, weight, mechanical properties, 
swelling, bioadhesion,  
in vitro stability, FTIR. 








Drug content, thickness, in vitro drug 
release, mucoadhesivity, swelling and 
erosion, surface pH, morphology (SEM), 
mechanical properties. 








Swelling, bioadhesion, in vitro drug 
release, phase solubility studies,  
DSC, FTIR. 










Bioadhesion, drug release, thickness, 
weight, folding endurance, drug content, 
surface pH, swelling, mechanical 
properties, in vivo efficacy. 
Singh et al. 
(2010) 





Particle surface morphology, particle size, 
zeta potential, DSC, mechanical 
properties, in vitro drug release. 
Meng et al. 
(2011) 
Glibenclamide Different grades of HPMC 
Casting/solvent 
evaporation 
Weight, thickness, surface pH, swelling, 
folding endurance, drug content, in vitro 





HCl Chitosan, gelatin 
Casting/solvent 
evaporation 
Thickness, weight, drug content, 
morphology, FTIR, TGA, DSC,  
swelling, in vivo residence time,  
in vitro drug release, drug permeation,  










Tensile strength, bioadhesion force, drug 
release, DSC, swelling, surface pH, folding 
endurance, thickness, weight,  




Abbreviations:  DSC: Differential scanning calorimetry     HPMC: Hydroxypropyl methylcellulose  
  TGA: Thermogravimetric analysis      SEM: Scanning electron microscopy 
  FTIR: Fourier transform infrared spectroscopy  XRD: X-ray diffractometry 
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2.6  FILMS FOR BUCCAL DRUG DELIVERY OF ARVS 
 
A thorough literature search revealed hundreds of reported studies on various classes 
of drugs formulated into buccal films for systemic delivery. It became evident that a gap 
existed in incorporating ARVs in buccal polymeric films (Morales and McConville, 2011, 
Ojewole et al., 2008, Sudhakar et al., 2006). To the best of the researcher’s 
knowledge, the only published paper thus far on buccal polymeric dosage forms of 
ARVs is of zidovudine polymeric patches recently produced by Reddy et al. (2012). 
Characterization studies were limited and did not include critical parameters such as in 
vitro permeation or mechanical properties. ARV buccal delivery systems have not been 
comprehensively investigated or characterised, which is clearly essential for 
formulation optimization. A detailed overview of buccal films are presented in the 
following section. 
 
2.6.1  Methods of Film Preparation 
 
There are two major methods commonly reported for the preparation of polymeric 
buccal films namely, the solvent evaporation method, and the other that is solvent free, 
called the hot-melt extrusion method (Morales and McConville, 2011). 
 
2.6.1.1  Film Casting and Solvent Evaporation 
 
The most widely reported method used to manufacture buccal polymeric films is the 
solvent evaporation method. This is largely due to the relatively simple process and low 
costs incurred at the laboratory scale (Morales and McConville, 2011). The method 
entails dissolving the drug and appropriate polymer(s), with or without plasticizers, in a 
suitable solvent or solvent mixture. This solution is then cast onto a suitable substrate 
or into a mold, and the solvent(s) are allowed to evaporate, leaving behind a solid 
polymeric film that contains the drug (Patel et al., 2011). 
 
A recent review by Morales and McConville (2011) highlighted some limitations 
associated with this method of film preparation: 
 
• Air bubbles introduced into the polymeric solution during the manufacturing 
process can result in films with an uneven surface and uneven thickness, 
therefore removal of air during preparation is a vital step for homogeneity 
reasons (Dixit and Puthli, 2009).  
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• The use of organic solvents during film preparation is another pressing concern. 
The problems concerning solvent collection, residual solvents in the films, and 
biological hazards to the environment and human health (Jones et al., 2013) 
should always be borne in mind when developing a buccal polymeric film.  
 
• Complex manufacturing methods using expensive equipment or emulsification 
below room temperature (Perumal et al., 2008b) have been reported. While 
producing a dosage form, efforts should be taken to simplify production 
methods and production costs must be kept to a minimum. 
 
• The problems with content uniformity was highlighted in a recent review paper 
(Morales and McConville, 2011) and have been addressed in our laboratory. 
Specially developed silicone-molded trays, with individual wells for film casting, 
resulting in improved uniformity of drug content, uniformity of mucoadhesive 
properties, in vitro drug release and thickness uniformity, were designed in our 
laboratory to address this problem and was reported by Perumal et al. (2008a). 
 
2.6.1.2  Hot-melt Extrusion 
 
The other method sometimes being used for buccal film preparation is hot-melt 
extrusion. In this technique of film preparation, a blend of suitable polymers, the active 
ingredient, and other excipients required for processing or formulation performance is 
molten and then forced through an orifice containing a die to yield uniformly dispersed 
granules, tablets or films (Morales and McConville, 2011).  
 
Cilurzo and co-workers (2008) prepared fast-disintegrating oral films using both the 
solvent casting/evaporation and hot-melt extrusion techniques. The casting method 
proved to be more advantageous, as the films resulted in the highest patient 
compliance and faster in vitro and in vivo disintegration times to achieve the desired 
drug release. A limited number of studies have been published where hot-melt 
extrusion was used to prepare mucoadhesive buccal films, with the majority being 
undertaken by a specific research unit (Prodduturi et al., 2005, Repka et al., 2005, 
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2.6.2  Types of Buccal Film Preparations 
 
Mucoadhesive buccal polymeric films can either be designed to deliver drugs 
systemically or to act only locally on the oral mucosa (Patel et al., 2011). 
 
There are three main types of buccal films (Hearnden et al., 2012):  
 
1. Films with a dissolvable matrix of polymers and drugs for administration to the 
buccal mucosa. These films can produce sustained drug release for treating 
conditions such as oral candidiasis and mucositis (Madhav et al., 2009). They 
dissolve slowly and completely, leaving no remains in the oral cavity.  
2. Films with an impermeable backing layer normally used for systemic drug 
delivery. They provide controlled drug release but can only deliver to a 
restricted area of the mucosa, thereby limiting the available dose. In addition, 
the impermeable layer remains behind which the patient has to remove.  
3. Films with a dissolvable impermeable backing layer, where the complete film 
eventually dissolves. They have the same controlled delivery as above, without 
the need to remove the film after the drug was released (Madhav et al., 2009).  
 
For controlled drug release, good mucoadhesion and suitable mechanical strength, 
polymers and drugs of opposing solubilities may often be required. While 
multipolymeric multilayered films and wafers have been prepared with drugs and 
polymers of opposing solubilities (Ding et al., 2012, Perugini et al., 2003), monolayered 
multipolymeric films (MMFs) offer more advantages, i.e. lower production costs, 
improved drug release, mucoadhesivity and size (Perugini et al., 2003). Limited 
formulation and characterization studies on MMFs with polymers and drugs of 
opposing solubilities have been reported. Furthermore, the methods employed to 
produce the aforementioned MMFs require carcinogenic solvents (Perugini et al., 
2003), involve the combination of two separate mixtures under high shear rates 
(Pendekal and Tegginamat, 2012), require emulsification below room temperature 
(Perumal et al., 2008b) or need multiple solvents with additional emulsifiers (Vasantha 
et al., 2011). In this study, a new technique, whereby drugs and polymers of opposing 
solubilities can be co-blended using a co-solvent to produce buccal MMFs, is reported. 
This method is simple, eliminates the need for emulsifiers, can be done at room 
temperature and requires minimal equipment. 
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2.6.3  Characterisation of Buccal Films 
 
Buccal films should be thin, flexible, sufficiently elastic yet resist breakage due to 
handling or oral application, display good mucoadhesive properties to ensure 
prolonged retention, and have predictable drug release. These characteristics need to 
be carefully evaluated during formulation development for optimization, regulatory 
approval and commercialization. Several techniques are reported in the literature to 
characterize and evaluate buccal polymeric films. These techniques investigate the 
physical properties of the films through mucoadhesive characteristics, in vitro 
permeation to in vivo absorption in humans (Nair et al., 2013). 
 
A review of the literature indicates that the main properties being evaluated in studies 
on buccal films are dosage form uniformity, mechanical properties, buccal 
performance, morphology, compatibility and drug release characteristics. The specific 
tests being undertaken by researchers to address these properties were identified from 
various experimental papers, and are summarised in the schematic below (Figure 2.6). 
Details on methods for the evaluation of films by these techniques can be found in the 
literature (Morales and McConville, 2011, Nair et al., 2013, Sudhakar et al., 2006). 
 
Figure 2.6: Film characterization methods. 
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2.7  EMERGING WORK ON NANO-ENABLED BUCCAL DRUG DELIVERY 
 
Recent developments in the field of buccal drug delivery show an increased interest 
towards nano-enabled buccal drug delivery systems (Giovino et al., 2012, Morales et 
al., 2013, Silva et al., 2012). The advantages of buccal drug delivery can be combined 
with that of the nanoparticulate drug delivery systems to provide a superior drug 
delivery system in terms of enhanced bioavailability and drug targeting. Table 2.6 gives 
an overview of all studies reported to date on these emerging nano-enabled buccal 
films. It can be seen that a very limited number of studies have been done to date in 
this emerging field, and antiretrovirals have yet to be investigated.  
 
The use of nanotechnology in HIV & AIDS therapy is warranted by benefits such as its 
versatility, nearly all types of drugs may be incorporated, relatively non-toxic 
biocompatible excipients can be used, drug-release modification is possible, the 
production costs are relative low, ease of producing nanoparticles, and the possibility 
for scale-up exists. Furthermore, nanoparticulate systems for ARVs may be of 
particular interest to achieve targeted delivery to HIV reservoirs (Shahiwala and Amiji, 
2007, Vyas et al., 2006b). 
 
A nanoparticulate system of particular interest is solid lipid nanoparticles (SLNs).  SLNs 
are prepared from lipids, which are solid at room temperature, and surfactants or 
stabilizers (Shegokar et al., 2011), in the nanometer size (< 1000 nm) range. 
Advantages of SLNs over other nanoparticulate systems include: increased stability 
(Shegokar et al., 2011), controlled drug release (Kuo and Chen, 2009), targeted drug 
delivery (Aji Alex et al., 2011, Chiappetta et al., 2013) and the incorporation of both 
hydrophilic (Ghadiri et al., 2012) and lipophilic (Kumar et al., 2007) drugs. Furthermore, 
SLNs lipids are biocompatible and organic solvents can be avoided during 
manufacturing processes (Mehnert and Mäder, 2012). 
 
As evident from Table 2.6, SLNs incorporated into buccal monolayered multipolymeric 
films (MMFs) have not been explored in the literature for any drug. There is a clear 
need to explore the use of SLNs and buccal polymeric films. Furthermore, DDI SLNs 
have not been successfully prepared (Table 2.7). As illustrated in Table 2.7, a wide 
range of ARVs have been successfully incorporated into SLNs, which are suitable for 
delivery via the oral or parenteral route.  
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By incorporating the drug in the form of nanoparticles into the buccal film, a reduction in 
dose-dependent side effects can be expected, as drug targeting to the required site of 
action can be achieved using a smaller dose. The additional reduced cost could make 
DDI more therapeutically useful once more. Incorporating multiple ARVs into 
nanoparticles can be accomplished to achieve multi-drug HAART regimens (Shibata et 
al., 2013). 
 
This study also explored the incorporation of DDI SLNs into the reported MMFs to 
investigate for potential of buccal drug delivery of an ARV using nano-enabled films. As 
a result, this study can be considered as a platform that opens up numerous 
possibilities for future development and formulation optimization studies for nano-
enabled buccal ARV films and DDI SLN formulations.  
 
Table 2.6: Emerging Nano-enabled buccal films. 
Active 
Ingredients 
Film Type & Preparation 
Methods 
Nanoparticulate System & 
Preparation Methods References 
Phenylephrine 
HPMC and Carbopol 934P 
Multi-layered patch with a 
microtablet containing the 
dry nanosuspension  
Nanosuspension prepared by wet 
stirred media milling or by high-
pressure homogenization 
Rao et al. (2011) 
Insulin 
(Protein) 
Chitosan films prepared by 
solvent casting / evaporation 
PEG-b-PLA copolymeric 
nanoparticles prepared by double 
emulsion solvent evaporation 





HPMC films prepared by 
solvent casting / evaporation 
Nanosuspensions prepared by 
wet stirred media milling 
Sievens-
Figueroa et al. 
(2012) 
Risperidone Semi-solid hydrogel using Carbomer 2001 
Glyceryl monostearate solid lipid 
nanoparticles prepared via 
homogenization/ultrasonication 





HPMC films prepared by 
solvent casting / evaporation 
Lysozyme-loaded-D,L-valine 
protein-coated nanoparticles 
prepared by antisolvent co-
precipitation 
Morales et al. 
(2013) 
Carvedilol 
Tri-layered films containing 
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Table 2.7: Overview of studies reporting on SLNs incorporating ARVs. 
ARV Excipients Preparation Methods 
Routes of 













particle size, zeta potential, 

















Particle size, zeta potential, 




Heiati et al. 
(1998) 






particle size, morphology, 
zeta potential, drug release 
and cell viability. 
Chattopadhy











particle size, zeta potential, 
morphology (FE-SEM), 
Nuclear magnetic 
resonance analysis,  
in vitro drug release. 
Kuo and 
Chen (2009) 







particle size, zeta potential, 
DSC, Wide angle X-ray 
scattering, Atomic force 
microscopy, in vitro drug 
release, in vivo studies, 
stability studies. 
Aji Alex et al. 
(2011) 







particle size, zeta potential, 
morphology (TEM), 
cytotoxicity studies. 











particle size, zeta potential, 
DSC, drug release, XRD, 
morphology (TEM),  
in vivo studies. 










Homogenization No data 
Entrapment efficiency, 
particle size distribution, 
morphology (FE-SEM), 







ATO, Tween 80 
Microemulsion 
method Parenteral 
Particle size, zeta potential, 
morphology (FE-SEM), 














Particle size, polydispersity 














Entrapment efficiency, drug 
loading, particle size, zeta 
potential, DSC, XRD, 
morphology (TEM), Atomic 
force microscopy, in vitro 
release, in vivo studies. 
Negi et al. 
(2013) 
*DODAB = dioctadecyldimethyl ammonium bromide 
 
 
       39 
 
Literature Review: HIV & AIDS and Buccal Drug Delivery Chapter Two 
 
2.8  DIDANOSINE AS A MODEL ARV FOR BUCCAL DELIVERY 
 
Didanosine (DDI) is a synthetic analogue of deoxyadenosine (Figure 2.7), and is 
commonly referred to as 2′,3′-Dideoxyinosine, while its systematic structural name (9 -
((2R,5S) -5- (hydroxymethyl) tetrahydrofuran -2-yl) -3H-purin-6(9H)-one) is used 
seldom. DDI has a molecular formula of C10H12N4O and a molecular weight of 236.23 
g/mol (Moffat et al., 2004). 
 
Figure 2.7: Chemical structure of didanosine. 
 
Many factors need consideration during development of a NDDS. Parameters related 
to the drug delivery system is of great importance and equally critical to consider is the 
physico-chemical and pharmacological properties of the drug.  
 
Solubility: DDI is sparingly soluble in water, freely soluble in dimethyl sulfoxide, 
slightly soluble in methanol and in 96 % ethanol (BP 2009). The solubility of DDI in 
water is pH-dependent and reported as 20.29 mg/mL (Sánchez-Lafuente et al., 2002a). 
 
Dissociation constant: DDI is an amphoteric compound that has a weakly acidic 
hydrogen atom on the hypoxanthine moiety and a number of basic nitrogen atoms 
(Figure 2.7). The apparent pKa of DDI in water, has been reported as 9.12 (Moffat et 
al., 2004), representing the basic properties of the molecule. An unionized form of a 
drug is more likely to interact with lipid membranes than a drug in the ionized form. By 
maintaining a pH range of between 6-7, amphoteric nucleoside analogues such as DDI 
may be kept in their unionized forms. Formulations are thus best prepared at pH 6-7 to 
readily promote absorption. 
 
Partition coefficient: The octanol/water partition coefficient [Log P(octanol/water)], as 
determined by the traditional shake-flask method, has been reported as -1.24 (Moffat et 
al., 2004), thereby suggesting DDI is hydrophilic. 
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Melting point/Thermal stability: DDI melts between 160 °C and 163 °C (Moffat et al., 
2004). Kasongo and co-workers (2011) determined the thermal stability of DDI to 
ensure no degradation product would form while manufacturing nanostructured lipid 
carriers (NLC) at high temperatures. DDI was proven to be thermostable beyond 80°C. 
Temperatures used to produce proposed buccal polymeric films (43°C, 24 hours) and 
solid lipid nanoparticles (80°C, 20 min) in this study would not lead to thermal 
degradation of DDI. 
 
Ultraviolet absorption: DDI’s maximum wavelength of absorption have been reported 
for numerous media: aqueous acid (pH 2) 248 nm; (ethanol) 250 nm; aqueous alkali 
(pH 12) 254 nm (Moffat et al., 2004). A typical ultraviolet (UV) absorption spectrum of 
DDI generated in this study is shown in Figure 2.8. A wavelength of 250 nm was used 
for in vitro analyses of DDI containing samples during formulation development and 
optimization studies. 
 
Figure 2.8:  A typical UV spectrum produced during evaluation of didanosine buccal 
 films prepared in this study. 
 
Pharmacological properties: DDI is a nucleoside reverse transcriptase inhibitor 
(NRTI), acts by competitive inhibition of HIV-1 reverse transcriptase and can also be 
incorporated into the growing viral DNA chain to cause termination (Katzung et al., 
2003). The severe side effects associated with long term use of NRTIs include lactic 
acidemia and severe hepatomegaly with steatosis. Side effects associated with DDI 
include dose-dependent pancreatitis, peripheral distal neuropathy, diarrhea, hepatitis, 
esophageal ulceration, cardiomyopathy, and central nervous system toxicity (Katzung 
et al., 2003, Rossiter, 2012). 
 
       41 
 
Literature Review: HIV & AIDS and Buccal Drug Delivery Chapter Two 
 
The oral bioavailability of DDI ranges from 30 to 40 %, depending on the formulation 
being administered. The oral bioavailability is reduced by up to 55 % if ingested within 
two hours after a meal. Maximum plasma concentrations are achieved within 
approximately one hour after oral administration (Tmax). The plasma elimination half-
life (t½) is reported to be only 1.3 to 1.6 hours (Sweetman, 2009). The low oral 
bioavailability combined with the short half-life necessitates frequent administration of 
large doses, leading to dose-dependent toxicities such as pancreatitis. 
 
At acidic pH, hydrolysis of the glycosidic bond between the sugar and the base 
moieties of DDI will inactivate the drug (Katzung et al., 2003). Originally, a buffered 
powder formulation of DDI was available that was subsequently replaced by chewable 
and dispersible buffered tablets with greater oral bioavailability (30–40 %). As the 
chewable tablets contain both phenylalanine (36.5 mg) and sodium (1380 mg), caution 
should be exercised in patients with phenylketonuria and those taking sodium-
restricted diets (Katzung et al., 2003). A new enteric-coated formulation was developed 
that further improved patient convenience and tolerability (Deshmukh et al., 2003), and 
is currently marketed as Videx EC® (Bristol-Myers Squibb, 2013), but challenges with 
using DDI in its current oral formulations still exists. 
 
Rapid degradation of DDI in the GIT due to acidic hydrolysis, together with the need for 
repetitive dosing, its short elimination half-life, dose-related toxicity and relatively low 
daily dosage (250–400 mg), make this drug a suitable candidate for incorporating into 
novel buccal polymeric films. Moreover, DDI’s favourable physico-chemical properties, 
such as adequate water solubility, octanol/water partition coefficient and thermal 
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2.9  CONCLUSION 
 
This chapter highlighted the current status of HIV & AIDS, its current drug therapy and 
the limitations associated with therapy. Strategies, including buccal polymeric films, 
aimed at addressing current limitations of ARV drugs were examined. This literature 
review showed that although buccal permeation investigations with antiretroviral drug 
solutions have confirmed their transbuccal delivery potential, studies on their 
formulation into delivery systems are lacking. Although multipolymeric monolayered 
films (MMFs) with drugs and polymers of opposing solubilities offer several advantages 
for the controlled release of drugs via the buccal route, more research still needs to be 
done in the area. Didanosine was identified as a model ARV due to its extensive first 
pass metabolism and short half-life, making it an ideal candidate for controlled release 
buccal delivery. 
 
It was also identified that emerging research have been exploring the use of nano-
enabled buccal drug delivery. Through this, a considerable scope for future 
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3.1   INTRODUCTION 
 
The following paper was published in an international peer reviewed journal and 
reports on original research: 
 
Jones, E., Ojewole, E., Pillay, V., Kumar, P., Rambharose, S., Govender, T., 2013. 
Monolayered multipolymeric buccal films with drug and polymers of opposing 
solubilities for ARV therapy: Physico-mechanical evaluation and molecular mechanics 
modelling. International Journal of Pharmaceutics, 455, 197-212. 
 
Ms E. Jones contributed to the design of the project, modification and optimisation of 
methods and preparation and characterisation of all polymeric films in terms of assay, 
in vitro drug release, in vitro permeations, transepithelial electrical resistance 
measurements, mucoadhesivity, mechanical strength and surface pH as well as 
interpretation of the data and writing of the paper. Mr S. Rambharose assisted Ms 
Jones with the LM/TEM histological evaluation section. Mr P. Kumar and Professor V. 
Pillay were collaborators and performed the molecular modelling studies. The 
remaining authors served as supervisor and co-supervisor. 
 
This chapter is presented in the required format of the journal and is the final revised 
accepted version. The published article (doi:10.1016/j.ijpharm.2013.07.037) can be 
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Although buccal permeation investigations with antiretroviral drug solutions have 
confirmed their transbuccal delivery potential, studies on their formulation into delivery 
systems are lacking. Multipolymeric monolayered films (MMFs) with drugs and 
polymers of opposing solubilities will offer several advantages for the controlled release 
delivery of didanosine (DDI) via the buccal route. The aim of this study was to employ a 
co-blending-co-plasticization technique for preparation of MMFs containing 
Eudragit®RS100 (EUD) and Hydroxypropyl methylcellulose (HPMC) and to undertake 
molecular modelling and in vitro characterizations. Uniform drug content (91%-105%) 
with low variability was obtained for all films. Co-blending of DDI:HPMC:EUD (1:1:10) 
was required to achieve controlled drug release. The buccal permeability potential of 
DDI from the MMFs was successfully demonstrated with a permeability coefficient of 
0.72±0.14x10-2 cm/h and a steady state flux of 71.63±13.54 µg/cm2h. Films had 
acceptable mucoadhesivity (2184 mN), mechanical strength (0.698 N/mm2) and 
surface pH (6.63). The mechanism inherent to the mucoadhesive and drug release 
profile performance of the MMFs was elucidated via static lattice molecular mechanics 
simulations wherein a close corroboration among the in vitro–in silico (IVIS) data was 
observed. These extensive physico-mechanical and molecular atomistic studies have 














Didanosine, Buccal, Films, Co-blended polymers, Physico-mechanical properties, 
Static lattice atomistic simulations. 
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1.0  INTRODUCTION  
 
Human Immunodeficiency Virus (HIV) infection and Acquired Immune Deficiency 
Syndrome (AIDS) commonly referred to as HIV & AIDS, have emerged as the leading 
cause of mortality worldwide and is the main cause of death in sub-Saharan Africa 
(Merson et al., 2008). While antiretrovirals (ARVs) have proven to be useful in the 
treatment and management of HIV & AIDS, several disadvantages including extensive 
first pass metabolism, gastrointestinal degradation, low bioavailability and short half-
lives (Li and Chan, 1999) limit their efficacy. Large doses, complex dosing regimens 
and multiple drugs contribute to reduced patient compliance (Chandwani et al., 2012). 
Poor drug solubility and limited membrane permeability also pose formulation 
difficulties (Sharma and Garg, 2010).  
 
The development of new chemical entities, novel drug delivery systems and alternative 
routes to deliver ARVs (Ojewole et al., 2008) are being explored to overcome these 
limitations. Novel drug delivery systems receiving increased attention include sustained 
release matrix tablets (Sánchez-Lafuente et al., 2002b), ceramic implants (Benghuzzi, 
2000), liposomes (Dubey et al., 2010) and nanoparticles (Kuo and Chung, 2011b). 
Alternate routes for delivery under investigation include: transdermal (Gerber et al., 
2008), nasal (Carvalho et al., 2013), vaginal (Johnson et al., 2010) and buccal delivery 
(Ojewole et al., 2012, Xiang et al., 2002). 
 
Drug delivery via the buccal route has recently emerged as a lucrative alternative to the 
oral route. Drugs can directly enter the systemic circulation and bypasses 
gastrointestinal degradation and first-pass hepatic metabolism, thereby improving 
bioavailability (Hoogstraate and Wertz, 1998). The buccal mucosa is easily accessible 
and more permeable than skin (Squier and Hall, 1985). Formulating the drug into a 
controlled release mucoadhesive dosage form may further improve drug delivery and 
patient compliance (Morales and McConville, 2011). Buccal transportation mainly 
occurs via passive diffusion across lipid membranes either via  paracellular or 
transcellular pathways  making this route suitable for both hydrophilic and lipophillic 
drugs (Patel et al., 2011). This is relevant considering HIV & AIDS is treated with 
multiple-drug regimens. The disadvantages associated with the buccal route of drug 
delivery are its low mucosal permeability, continuous secretion of saliva leading to 
dilution of drug and the need for formulation approaches to promote retention on the 
mucosae (Patel et al., 2011).  
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To date, reports regarding buccal permeability of antiretrovirals remain limited. In vitro 
drug permeability studies with solutions of zalcitabine (Shojaei et al., 1999, Xiang et al., 
2002), didanosine (Ojewole et al., 2012) and tenofovir (Rambharose et al., 2013) have 
been reported. To the best of our knowledge, the only report thus far on buccal 
polymeric dosage forms of ARVs is of zidovudine polymeric patches recently produced 
by Reddy et al. (2012). Characterization studies were limited and did not include critical 
parameters such as in vitro permeation or mechanical properties. ARV buccal delivery 
systems have not been comprehensively investigated or characterised and it is clearly 
essential for formulation optimization.  
 
Various mucoadhesive buccal dosage forms are being investigated for different classes 
of drugs, which include adhesive tablets (Cappello et al., 2006), gels (Ayensu et al., 
2012b), ointments (Petelin et al., 2004), patches (Vasantha et al., 2011), and more 
recently films (Sievens-Figueroa et al., 2012, Abruzzo et al., 2012). Films may be 
preferred over tablets in terms of flexibility and comfort. They can circumvent the 
relatively short residence time of oral gels on the mucosa, which is easily washed away 
by saliva (Ahn et al., 2001, Okamoto et al., 2001). Polymeric films formulated for 
controlled drug release could also decrease dose-related side effects and improve 
patient compliance. A polymer for buccal films should adhere easily and sufficiently to 
the buccal mucosa, should have sufficient mechanical strength, should demonstrate 
penetration enhancement and provide for controlled release of the drug. Single 
polymers often fail to demonstrate all the ideal characteristics. To overcome this 
problem, researchers have been focusing on blending of polymers with similar 
solubilities (Abruzzo et al., 2012, Dubolazov et al., 2006, Juliano et al., 2008).  
 
For controlled drug release, good mucoadhesion and suitable mechanical strength, 
polymers and drugs of opposing solubilities may often be required. While 
multipolymeric multilayered films and wafers have been prepared with drugs and 
polymers of opposing solubilities (Ding et al., 2012, Perugini et al., 2003), monolayered 
multipolymeric films (MMFs) offer more advantages i.e. lower production costs, 
improved drug release, mucoadhesivity and size (Perugini et al., 2003). Limited 
formulation and characterization studies on MMFs with polymers and drugs of 
opposing solubilities have been reported. Further, the methods employed to produce 
the aforementioned MMFs  require carcinogenic solvents (Perugini et al., 2003), 
involve the combination of two separate mixtures under high shear rates (Pendekal and 
Tegginamat, 2012), require emulsification below room temperature (Perumal et al., 
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2008b) or need multiple solvents with additional emulsifiers (Vasantha et al., 2011). In 
this paper a new technique whereby drugs and polymers of opposing solubilities can 
be co-blended using a co-solvent to produce buccal MMFs is reported. This method is 
simple, eliminates the need for emulsifiers, can be done at room temperature and 
requires minimal equipment. Limited studies on Eudragit® RS 100 (EUD) in 
combination with hydroxypropyl methylcellulose (HPMC) for buccal films have been 
reported (Koland et al., 2010, Mishra et al., 2012). These studies involved complex 
preparation methods and lacked evaluation of critical physico-mechanical properties. 
Molecular modelling to identify the mechanism of interaction between these two 
polymers and their suitability for combined use and indeed for any other buccal delivery 
system has not been previously reported. Therefore such physico-mechanical 
evaluation and molecular modelling of MMFs is essential for formulation optimization 
and facilitating a mechanistic understanding of MMFs.  
 
Didanosine was selected as a model ARV due to its extensive first pass metabolism 
and short half-life making it an ideal candidate for controlled buccal delivery. The aim of 
this study was, therefore, to use a simplified method to prepare and characterize 
monolayered mucoadhesive films comprising of various ratios of co-blended EUD and 
HPMC for buccal delivery of didanosine. Films prepared by the solvent 
casting/evaporation technique were evaluated in terms of drug content uniformity, drug 
release, permeability, mucoadhesivity, mechanical properties and surface pH. Static 
lattice atomistic simulations (SLAS) were performed to identify the suitability of the 
polymeric blend for buccal film formulations and to identify correlations between in vitro 
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2.0  MATERIALS AND METHODS 
 
2.1  MATERIALS 
 
Didanosine (DDI) was purchased from Ruland Chemistry Co., Ltd. (Nanjing, China) 
and used as received. Hydroxypropyl methylcellulose (HPMC), triethyl citrate (TEC) 
and mucin (Sigma–Aldrich, UK) were purchased and used as received. Eudragit® RS 
100 (EUD) (Evonik Rohm GMBH, Germany) was donated by Degussa Africa (Pty) Ltd. 
All other reagents used [NaCl, Na2HPO4, KH2PO4, NaOH, HCl, MeOH, EtOH and 
Glycerol (GLY)] were of analytical reagent grade. Purified water used throughout the 
studies was produced in the laboratory with a Milli-Q purification system (Millipore 
Corp., USA). 
 
Phosphate buffered saline (PBS) used for in vitro drug release, permeation and 
mucoadhesion studies had the following composition per litre of distilled water: 2.38 g 
Na2HPO4·10H2O, 0.19 g KH2PO4, 8 g NaCl and adjusted to pH 6.8 or pH 7.4 with 
hydrochloric acid or sodium hydroxide as required (Peh and Wong, 1999). 
 
2.2  METHODS 
 
2.2.1  Preparation of Films via Co-blending 
 
Films were prepared using the solvent casting and evaporation method. For this study 
silicone moulded trays (SMTs) with individual wells of 6 cm2 were used instead of 
conventional film casting trays, since it has been shown in our previous publication that 
SMTs enhance drug content uniformity, and reduce the variability in mucoadhesivity as 
well as drug release (Perumal et al., 2008a).  
 
Multipolymeric films comprising of DDI, HPMC and EUD in various ratios were 
prepared as shown in Table 3.1. Specified quantities of EUD and TEC as its plasticizer 
together with HPMC and GLY as its plasticizer were dissolved in 40 mL methanol in a 
100 mL volumetric flask. DDI and 40 mL water was added to this and sonicated until 
the drug has been dissolved. The mixture was made up to volume with 50 % methanol 
in water and agitated by hand at room temperature until a homogenous solution 
resulted. Preformulation studies informed the specific formulation variables to use. The 
plasticizer content for both polymers was kept constant at 30 % (w/w) of polymer 
weight for all ratios prepared. 
 
Thereafter 2 mL of each polymeric solution containing 20 mg of DDI was syringed into 
each 6 cm2 well of the SMT containing Teflon coated Perspex inserts. The drug–
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polymeric mixture was allowed to dry in an oven (Series 2000, Scientific, SA) at 43 °C 
for approximately 24 h, until the solvent had evaporated and constant film weight was 
achieved. Films were removed from the moulds and stored using wax paper and foil in 
a desiccator at room temperature (23 °C) up to a maximum of three months until further 
use.  
 
Table 3.1: Composition of the buccal film formulations (DDI:HPMC:EUD). 
Ingredients 
(% w/v) 
Effect of HPMC  Effect of EUD 
1:0.25:10 1:0.5:10 1:0.75:10 1:1:10 1:0.5:5 1:0.5:7.5 1:0.5:10 1:0.5:15 1:0.5:20 
DDI 1 1 1 1 1 1 1 1 1 
HPMC 0.25 0.5 0.75 1 0.5 0.5 0.5 0.5 0.5 
GLY 0.075 0.15 0.225 0.3 0.15 0.15 0.15 0.15 0.15 
EUD 10 10 10 10 5 7.5 10 15 20 
TEC 3 3 3 3 1.5 2.25 3 4.5 6 
 
2.2.2  Characterization of Films 
 
2.2.2.1  Weight and Thickness Uniformity 
 
For weight uniformity three films per batch were randomly selected and individually 
weighed on an electronic balance (Metller Toledo AB204-S., Switzerland). The 
thicknesses of the films were measured using a digital micrometer (Mitutoyo Co., 
Japan) with an accuracy of 0.001 mm. Thicknesses were measured in five different 
locations (centre and four corners) of the films. Results are represented as a mean and 
standard deviation of the replicate determinations. 
 
2.2.2.2  Assay of Films 
 
The assay solvent consisted of 80 % ethanol in water. A 6 cm2 film as a unit from the 
SMT was dissolved in approximately 40 mL of the assay solvent in a 100 mL 
volumetric flask before making up to volume with the same assay solvent. Following 
appropriate dilution (1 in 10), the drug content in the samples was quantified using a 
UV spectrophotometer (Shimadzu 1650 PC, Japan) at a wavelength of 250 nm. All 
assays were performed in triplicate. 
 
A calibration curve of DDI concentration versus absorbance was plotted across a 
concentration range from 0.1 to 50 µg/mL and a linear response was found (r2 = 
0.9997). The UV methodology was also successfully validated in terms of specificity, 
linearity, precision, accuracy and robustness (data not shown). 
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2.2.2.3  In Vitro Drug Release 
 
A modified BP2009 Type II paddle dissolution test apparatus (Erweka DTR-6., 
Germany) was employed to determine in vitro drug release of the films. The dissolution 
studies were carried out in 900 mL PBS adjusted to pH 6.8 and maintained at 37 ± 0.5 
°C; with a stirring speed of 50 rpm. The film size required for dose delivery (6 cm2) was 
used. The film was placed into a stainless steel wire mesh basket and dropped into the 
dissolution vessel at the start of the experiment. A wire mesh basket was used, instead 
of attaching a film to a glass slide with adhesives as commonly reported (Nair et al., 
2013), in an attempt to limit interference with drug release. Aliquots of 6 mL samples 
from the dissolution medium were collected at predetermined time intervals of 15, 30, 
45, 60, 90, 120, 150, 180, 240, 300 and 360 min using a syringe and in line filtration 
(0.45 μm).  An equal volume (6 mL) of fresh PBS was replaced into each dissolution 
vessel, to ensure that a constant volume of dissolution medium was maintained 
throughout the duration of the study. The filtered samples were quantified for drug 
using a UV spectrophotometer (Shimadzu 1650 PC, Japan) at a wavelength of 250 nm. 
The results are represented as the average of three films. 
 
2.2.2.4  In Vitro Permeation 
 
In vitro permeation experiments were performed on the 1:0.5:10 formulation to confirm 
the permeability potential of DDI incorporated into multipolymeric films. Porcine buccal 
mucosa was used as a biological membrane for these experiments due to the many 
similarities to the human buccal mucosa as highlighted by Shojaei (1998) and 
Sudhakar et al. (2006). 
 
Porcine buccal mucosa was excised from domestic pigs (30-40 kg) immediately upon 
euthanasia at the university’s biomedical research unit after obtaining necessary ethical 
clearance (011/12/Animal). Excess adipose and connective tissue were cut away from 
the mucosal specimens leaving the mucosa with an average thickness of (665 ± 72 
µm). Samples were wrapped in foil before being snap-frozen in liquid nitrogen and 
stored at -85 °C in a biofreezer for up to 3 months (Van Der Bijl, 1998). 
 
In vitro permeation experiments on DDI films were performed similar to in vitro 
permeability studies of DDI solutions recently reported (Ojewole et al., 2012). On the 
day of the experiments, frozen buccal mucosal specimens were allowed to thaw and 
equilibrate in PBS pH 7.4 to regain elasticity temporarily lost while frozen. Franz 
diffusion cells (PermeGear, Inc., USA) each with a diffusional area of 0.786 cm2 were 
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used for the in vitro permeation experiments. The buccal mucosa and polymeric film 
were mounted between the donor and receptor compartments using the two membrane 
holders. Two millilitres PBS at pH 6.8, simulating human saliva (Peh and Wong, 1999), 
was placed on the film in the donor compartment while the receptor compartment 
contained 27 mL PBS pH 7.4 maintained at 37 °C (by means of a surrounding jacket) 
and stirred constantly.  
 
At predetermined time intervals over 360 min, samples (27 mL) were taken from the 
receptor compartments and replaced by drug-free PBS. Similar to dissolution studies 
samples were immediately filtered through a 0.45 μm membrane filter and the drug 
content was quantified using a UV spectrophotometer (Shimadzu 1650 PC, Japan) at a 
wavelength of 250 nm.  A minimum of three replicates were performed. 
 
The viability of the mucosa was assessed by transepithelial electrical resistance 
(TEER) measurements using a Millicell ERS meter (Millipore, USA) connected to a pair 
of chopstick electrodes (STX01). TEER measurements were taken across the mucosa 
before and at the end of, the permeation experiment (Dezani et al., 2013) and 
thereafter following exposure to fresh PBS pH 6.8 for 60 min (Chen et al., 2009). 
 
The cumulative amount of DDI permeated per unit surface area was plotted versus 
time. The steady state flux (Jss) across the mucosal membrane was determined from 
the linear portion of the permeation graph by linear regression analysis (Microsoft Excel 
2010).  The permeability coefficient (P) was calculated using the following equation 










Where dQ/dt is the cumulative amount (Q) of DDI which permeated into the receptor 
compartment per unit time (t), A the active cross-sectional area (0.786 cm2) available 
for diffusion and Cd is the drug concentration in the donor compartment. 
 
2.2.2.5  Histological Evaluation 
 
Histological studies were performed to evaluate for pathological changes occurring in 
cell morphology and tissue organization. Directly after excision of mucosa, untreated 
buccal mucosa was transferred from normal saline into 10 % buffered formalin without 
any equilibration in PBS and served as the control. Treated samples comprised of 
buccal mucosae that were exposed to PBS only, or a placebo film or drug loaded film 
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(1:0.5:10). Permeation experiments were performed as described previously in Section 
2.2.2.4, without drug quantification (Rambharose et al., 2013). At the end of the 
experiment the buccal mucosa was cut into cross sections. The samples for light 
microscopy were fixed in 10 % buffered formalin for 7 days, washed in water, 
dehydrated in graded ethanol and, after permeation in xylene, embedded in paraffin 
using standard procedures. Samples were cut into sections (1 μm thick) on a 
microtome and stained with hematoxylin and eosin (H&E). Sections were examined 
using a light microscope (Nikon 80i, Japan), and bright field images were digitally 
captured using NIS Elements D software and a camera (Nikon U2, Japan). Samples for 
transmission electron microscopy (TEM) were collected under the same conditions. 
They were fixed for 24 hours (4 °C) using Karnovsky’s fixative buffered to pH 7.2, 
embedded in epoxy resin, cut into ultrathin section (90 nm) and contrasted with uranyl 
acetate and lead citrate using standard protocols before viewing with a transmission 
electron microscope (JEOL 1010, Japan). All experiments were performed using a 
minimum of three replicates. 
 
2.2.2.6  Mucoadhesivity of Films 
 
The effects of the different polymeric ratios on the mucoadhesive properties were 
studied using methods adapted from (Ayensu et al., 2012a) and (Perumal et al., 
2008b). A TA.XT2i Texture Analyser (Stable Micro Systems, UK) equipped with a 5 kg 
load cell in tension mode, removable 2 cm x 3 cm aluminium probes, and Texture 
Expert™ software were used for this purpose. 
 
Film samples (n=3), 30 mm long x 20 mm wide, and free from physical imperfections 
were individually attached to probes using double sided adhesive tape. The probes 
were attached to the upper movable arm of the TA.XT2i. A Petri-dish containing 
solidified 10% (w/v) gelatine gel, simulating buccal mucosa, was clamped into place on 
the stationary platform of the TA.XT2i (Ayensu et al., 2012a).  Two millilitres of 30% 
(w/v) mucin at 37 °C was spread on the surface of the gelatin immediately prior to 
testing (Perumal et al., 2008b). The film, securely attached to the probe, was allowed to 
hydrate for 120 seconds in PBS pH 6.8 before being brought into contact with the 
mucin covered gelatin. The film was held in place with a force of 100 grams for 60 
seconds before the mobile arm was raised. Parameters used were pre-test speed: 0.5 
mm/s; test speed: 0.5 mm/s and post-test speed: 1 mm/s. The mucoadhesive 
performance of the samples was determined by measuring the Maximum Detachment 
Force (MDF) (mN) and work (mJ). The MDF represents the maximum force required to 
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detach the film from the mucin covered gelatin. The area under the force/distance 
curve was also determined to represent the work required for detachment of the two 
systems (mucin/polymeric film) (Eouani et al., 2001). A minimum of 9 replicate 
determinations were performed. 
 
2.2.2.7  Mechanical Testing 
 
Mechanical properties of the films were studied as a function of various polymer ratios 
prepared. A TA.XT2i Texture Analyser (Stable Micro Systems, UK) equipped with a 5 
kg load cell, TA-96 grips and Texture Expert™ software were utilized for this purpose. 
 
Individual film samples (n=5), 30 mm long by 20 mm wide with varying thickness (Table 
3.2), and free from physical imperfections were held between the grips (TA-96). The 
grip separation was set at 15 mm. A sheet of Teflon was attached to the surface of the 
grips via double-sided tape to prevent the film being cut by the grooves of the grips. 
During measurement, the film was pulled by the top grip at a rate of 1 mm/s to a 
distance of 150 mm before returning to the starting point. Data acquisition was 
terminated when the film ruptured completely. The data of the film samples that failed 
at, and not between, the grips were not utilized in the evaluation of the mechanical 
properties. The force and elongation were measured when the films broke. 
 
The tensile strength, percent elongation, and Young’s modulus were used as indicators 
of the mechanical properties of the films. Mechanical properties of the films were 






Young’s modulus was determined from the slope of the initial linear portion of the 
stress-strain plots generated with the Texture Expert™ software.  
 
A rupture test was also performed to assess the mechanical film properties. A film 
support rig with an exposed area of 0.786 cm2 was attached to the heavy duty platform 
of the TA.XT2i Texture Analyser. Individual film samples (n=3) were clamped between 
the film support rig before passing a 5 mm stainless steel ball probe through a sample 
at 1 mm/s in compression mode. The force (N) required to rupture the film was 
measured (Sievens-Figueroa et al., 2012). 
100
length original
length in increase(%) break at Elongation
(mm) film of thickness  (mm) width
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2.2.2.8  Surface pH 
 
Saliva has a natural buffering capacity (Bardow et al., 2000) and its pH ranges from 5.6 
to 7 (Sudhakar et al., 2006). Buccal formulations should be within this range to avoid 
causing mucosal irritation. The surface pH of films was determined using methods 
adapted from (Cavallari et al., 2013) to assess for any potential buccal mucosa 
irritation. The film was allowed to swell in 15 mL PBS as simulated saliva at pH 6.8 and 
the pH was measured at predetermined time intervals over 6 hours. The film was 
carefully removed from the PBS, pH paper (Hydrion MicroFine, Micro Essential 
Laboratory, USA) was placed on its surface and the pH was measured. Results are 
represented by the mean of three measurements. 
 
2.2.3  Establishment of the Polymeric Complexation Profile and Potential Impact 
 on Mucoadhesion and Drug Release via SLAS 
 
All modelling procedures and computations, including energy minimizations in 
Molecular Mechanics, were performed using HyperChem™ 8.0.8 Molecular Modelling 
Software (Hypercube Inc., Gainesville, FL, USA) and ChemBio3D Ultra 11.0 
(CambridgeSoft Corporation, Cambridge, UK). The 3D structure of EUD was 
archetyped using ChemBio3D Ultra in its syndiotactic stereochemistry as a 3D model, 
whereas the structure of HPMC (4 saccharide units) was built from standard bond 
lengths and angles using the Sugar Builder Module on HyperChem 8.0.8. The 
structures of GLY and TEC were constructed with natural bond angles. The structure of 
the glycosylated mucopeptide analogue (MUC) mucin was generated using the 
sequence editor module on HyperChem 8.0.8. The glycosylation was performed at the 
threonine amino acid residues. The models were primarily energy-minimized using the 
MM+ Force Field algorithm and the resulting structures were once again energy-
minimized using the AMBER 3 (Assisted Model Building and Energy Refinements) 
Force Field algorithm. The conformer having the lowest energy was used to develop 
the polymer-polymer; polymer-plasticizer; and polymer-mucin complexes. A complex of 
one polymer molecule with another was assembled by parallel disposition and the 
energy-minimization was repeated to generate the final models: HPMC-GLY, EUD-
TEC, HPMC-EUD, HPMC-GLY/EUD-TEC, HPMC-MUC, EUD-MUC, and HPMC-MUC-
EUD. Full geometrical optimization was conducted in vacuum employing the Polak–
Ribiere Conjugate Gradient method until an RMS gradient of 0.001 kcal/mol was 
reached (Kumar et al., 2012). 
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2.2.4  Statistical Analysis 
 
All calculations were undertaken with Microsoft Excel® (Microsoft Office 2010, USA). A 
minimum of three replicates were performed and results are expressed as mean ± SD. 
Statistical analysis of data were performed using GraphPad Prism, Version 5 
(GraphPad Software., Inc., USA). One-way ANOVA followed by Dunnett’s multiple 
comparisons test was used to determine statistical significance. p-Values of p < 0.05 
were considered significant.  
 
3.0   RESULTS AND DISCUSSION 
 
3.1  PREPARATION OF FILMS VIA CO-BLENDING 
 
During preliminary studies, monopolymeric films containing DDI and either HPMC, as a 
hydrophilic polymer, or EUD, as a hydrophobic polymer, were prepared. However 
these films were deemed unsuitable for drug delivery due to unfavourable physico-
mechanical film properties (data not shown). Monopolymeric films exhibited undesired 
drug release kinetics, had irregular surfaces and unsuitable mechanical strength. 
Monolayered multipolymeric co-blended films (MMFs) were prepared thereafter with 
HPMC and EUD to improve film characteristics. Instead of using carcinogenic solvents 
(Perugini et al., 2003), complex mixing and emulsification methods (Pendekal and 
Tegginamat, 2012, Perumal et al., 2008b) or multiple solvents with additional 
emulsifiers (Vasantha et al., 2011) as previously reported, our group used a simple 
method that eliminated the need for homogenization and cooling as well as the use of 
complex or carcinogenic solvents and additional emulsifiers, to produce MMFs. We 
simply used methanol as the co-solvent in which the hydrophobic EUD as well as the 
hydrophilic DDI could dissolve. Methanol is miscible with water and allowed for 
sufficient swelling of HPMC in the aqueous medium. Multipolymeric monolayered films 
(MMFs), containing polymers of opposing solubilities and DDI, were successfully 
prepared using this simplified co-blending technique. SLAS results described under 
Section 3.8.2 indicate that the two polymers and two plasticizers form a stable quadra-
molecular system with the total energy of stabilization being six times higher than that 
of only the polymers in combination. It thereby supported the choice of polymers and 
plasticizers for the “novel co-blending-co-plasticizing strategy” employed in this study.   
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Figure 3.1:  Digital photographs of 1:0.5:10 (DDI:HPMC:EUD) monolayered 
multipolymeric films. 
 
The films generated by this simplified technique were translucent to opaque, thin, 
flexible and their surface appeared homogenous (Figure 3.1). The drug-polymeric 
casting solution prepared using the co-blending technique was also completely 
homogenous and no phase separation occurred upon drying of the films. Drying for 24 
h at 43 °C did not pose stability concerns as Kasongo et al. (2011) established 
didanosine’s thermal stability in excess of 85 °C. Limited drug precipitation was also 
noted. The average thickness and weight of the films ranged from 124 to 666 µm and 
159 to 556 mg respectively, increasing proportionally as polymer content increased 
(Table 3.2).  Drug content uniformity across buccal films is a major problem as 
highlighted in the literature (Morales and McConville, 2011). By using similar silicone 
moulded trays with individual wells for film casting as previously investigated by our 
group (Perumal et al., 2008a) we were able to overcome problems with drug content 
uniformity (Table 3.2). Drug content values ranged from 91 % to 105 % with low CV 
values of less than 6 % indicating good drug content uniformity. All ratios prepared of 
monolayered multipolymeric films were homogenous, had limited drug precipitate and 
acceptable drug content uniformity.  
 
Table 3.2:  Effect of polymer ratios on drug content uniformity, thickness and film 
weight. (Mean ± SD values; n = 3). 















 1:0.25:10 91.17 ± 0.85 0.93 209.40 ± 17.40 8.31 243.53 ± 10.51 4.32 
1:0.5:10 95.62 ± 5.41 5.66 299.60 ± 25.00 8.34 293.60 ± 1.50 0.51 
1:0.75:10 91.69 ± 2.11 2.30 308.07 ± 26.97 8.75 306.10 ± 2.52 0.82 











1:0.5:5 96.79 ± 0.36 0.37 124.13 ± 2.64 2.13 159.03 ± 0.96 0.60 
1:0.5:7.5 98.06 ± 2.36 2.41 205.20 ± 3.60 1.75 228.67 ± 0.72 0.32 
1:0.5:10 95.62 ± 5.41 5.66 299.60 ± 25.00 8.34 293.60 ± 1.50 0.51 
1:0.5:15 102.83 ± 3.06 2.98 434.33 ± 24.23 5.58 420.90 ± 10.19 2.42 
1:0.5:20 105.24 ± 1.69 1.60 666.47 ± 11.60 1.74 556.13 ± 4.92 0.88 
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3.2  IN VITRO DRUG RELEASE 
 
The influence of HPMC and EUD on the drug release of DDI MMFs were studied. 
Figure 3.2a shows the drug release profiles of DDI films prepared using increasing 
amounts of HPMC. An increase in HPMC led to increase in drug release while still 
maintaining controlled release profiles with no significant dose dumping. This increased 
drug release could be attributed to the hydrophilic nature of HPMC, which can erode 
more readily (Morales and McConville, 2011), thereby releasing the drug into the 
dissolution medium (33% within the 1st hour for 1:1:10). In addition to polymer solubility, 
molecular mechanistic simulations (Section 3.8.3) also showed that comparatively 
higher concentrations of HPMC-GLY will make the quadra-molecular architecture less 
stable. This leads to an increase in hydrophillicity and chain relaxation or degradation 
which causes increased drug release. Although drug release increased with increasing 
HPMC, the controlled drug release seen with all four profiles (Figure 3.2a) was due to 
the incorporation of EUD, a hydrophobic polymer, into the multipolymeric films.  
                                                                 
 
Figure 3.2 (a): Effect of HPMC on DDI release from multipolymeric films.   
 
The effect on drug release upon altering the EUD content of the multipolymeric films 
was also investigated. Figure 3.2b shows the drug release profiles of DDI films 
prepared using increasing amounts of EUD and constant amounts of HPMC. 1:0.5:5 
and 1:0.5:7.5 showed very rapid drug release. 80 % of the loaded drug was release 
from 1:0.5:5 within the first 15 minutes. Rapid drug release systems would be 
unfavourable for the delivery of DDI, as frequent drug administration would lead to 
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decreased patient compliance. Further increase in EUD content in the films led to 
decreased rates of drug release. It is possible to achieve controlled drug release with 
changing the ratios of polymers used in the formulation. Drug release retardation could 
be attributed to the hydrophobic nature of the EUD and the resultant lower solubility in 
the aqueous dissolution medium and slower rate of film erosion (Magdy I. Mohamed et 
al., 2011). The low aqueous solubility of EUD prevented free and deep water 
penetration into the film, thereby only allowing the DDI that was near the external 
surface of the film to be initially released into the dissolution medium (Perumal et al., 
2008b). The molecular mechanistic model employed in this study (Section 3.8.3) 
indicated that the presence of the stable EUD-TEC complex increase the stability of the 
films leading to slower drug release since there would be less tendency of the 
stabilized system to undergo a change in terms of chain relaxation or film degradation.  
 
Blending of EUD and HPMC polymers were necessary to obtain a desired controlled 
release profile of DDI. Molecular mechanistic simulations discussed in detail in Section 
3.8.3 provided additional supportive information to understand drug release profiles 
when blending polymers of opposing solubilities. 
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3.3  IN VITRO PERMEATION 
 
It is recognized that the bioavailability of drugs administered via the buccal route can 
be greatly influenced by the permeation rate through the buccal mucosal membrane 
(Morales and McConville, 2011). Limited work has been published regarding buccal 
permeability of antiretrovirals. Thus far the buccal permeability potential of only drug 
solutions containing zalcitabine (Shojaei et al., 1999, Xiang et al., 2002), didanosine 
(Ojewole et al., 2012) or tenofovir (Rambharose et al., 2013) have been published. In 
terms of drug delivery systems for the buccal route, buccal patches for zidovudine has 
been reported on but, permeability of drug across the mucosa was not reported. The 
buccal permeability potential of DDI from 1:0.5:10 films were investigated due to their 
potentially suitable mucoadhesion and drug release (Figure 3.3). The non-linear portion 
of the plot was considered as the lag time and it was the time required for steady state 
permeation to be achieved. A lag time of 45 minutes in this case is acceptable since 
the formulation under investigation will be for controlled release. In this study, we show 
that the drug can be released from the buccal film and can permeate across the 
mucosa as evidenced by a permeability coefficient of 0.72 ± 0.14 x10-2 cm/h and a 
steady state flux (Jss) value of 71.63 ± 13.54 µg/cm2h. The slope of the linear portion 
(R2 = 0.9932) of the plot was used to determine the Jss. The flux value (71.63 ± 13.54  
µg/cm2h) obtained in this study compares favourably to that achieved in permeation 
studies performed on DDI solutions only as recently reported by (Ojewole et al., 2012). 
Therefore these experiments indicate that the flux was not adversely affected by the 
formulation of DDI into a film with polymeric film components. The data thus confirms 
the potential of DDI being delivered transbuccaly via multipolymeric films and can be 
used for improving HIV and AIDS drug therapy. DDI is a hydrophilic drug, and passive 
diffusion should have preference towards the paracellular pathway (Hassan et al., 
2010, Sandri et al., 2006).  Several other classes of drugs incorporated into buccal 
polymeric films exhibited similar or lower flux values (Diaz del Consuelo et al., 2007, 
Pendekal and Tegginamat, 2012) and were considered as having potential for buccal 
delivery.  
 
Transepithelial electrical resistance (TEER) measurements can be used as an indicator 
of epithelial viability for mucosal permeation experiments (Holm et al., 2013, 
Muendoerfer et al., 2010). There are currently limited reported TEER studies with 
buccal permeation experiments specifically and therefore standardization remains to be 
developed. The reported values in these limited available studies vary widely (136 ± 17 
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to 950 ± 392 Ω/cm2) (Holm et al., 2013, Nielsen and Rassing, 2002). The TEER value 
across the buccal mucosa prior to the permeation experiment in this study was found to 
be 144 ± 12 Ω/cm2. After 6 hours of permeation this value decreased to 109 ± 21 Ω/cm2 
(24 % reduction). 60 min after removal of the DDI films and exposure to fresh PBS, the 
TEER increased again to 123 ± 12 Ω/cm2, which is a 14.5 % difference of the baseline 
value. This signified a return towards the initial measured integrity. The TEER values 
obtained in this study appear to be within the reported range and the overall 
percentage change also indicates that mucosal integrity was not irreversibly affected 
(Kowapradit et al., 2010). In addition, the  extent of TEER changes before and after the 
permeation experiments also compares favourably to reported studies using rat 
intestinal segments (Dezani et al., 2013) and porcine nasal mucosa  (Sintov et al., 
2010) for drug permeation assessments. The TEER values also correlate with the 
histomorphological studies (Section 3.4) which further confirmed that integrity and 
viability of the tissue was maintained. 
 
The buccal permeation potential of DDI demonstrated in this study therefore warrants 




Figure 3.3: Cumulative amount of DDI permeated per unit surface area versus time 
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3.4  HISTOMORPHOLOGICAL EVALUATIONS 
 
While buccal permeation studies on drug solution are extensively reported, reports on 
the effect of polymeric films on buccal mucosa morphology remain limited. Buccal films 
are often designed for prolonged retention on the mucosa and therefore assessment of 
histological effects of the drug and the polymeric film on the mucosa is essential. 
Histomorphological effects of the control/untreated and the treated porcine buccal 
mucosae (PBS alone, PBS + Placebo Film and PBS + Drug Loaded Film) were 
assessed. The morphology of porcine buccal mucosa and similarities between it and 
human buccal mucosa has been described in detail previously (Madhav et al., 2009, 
Shojaei, 1998, Sudhakar et al., 2006). 
 
The mucosa lining the buccal cavity is stratified squamous epithelium with a high 
recovery rate (Squier and Hall, 1985).  Since this mucosa is multilayered the cell 
structure differs as the cells transcends from the basal lamina to the mucosal surface, 
with cells becoming more flattened in appearance and more closely packed at the 
surface as compared to basal cells that appear more cuboidal in shape with more 
distinguishable intercellular spaces. This epithelium remains unkeratinized as an 
adaptation to its main functions which is to withstand abrasion due to mastication and 
also at the same time remain lubricated to protect against mechanical abrasion 
(Shojaei, 1998). Any particle that is able to permeate this mucosal lining has to travel 
either via transcellular or intracellular pathways to the basal membrane and enter the 
circulation present in the lamina propria.  
 
The light microscopy (LM) micrograph of the control slides (Figure 3.4a) closely 
resembled the above description with cells progressively getting flatter and more 
closely packed at the surface and basal cells being more distinguishable from each 
other. The PBS treated samples also appeared very similar to the controls, which 
correlate with other similar studies (Ojewole et al., 2012). Both the placebo film (Figure 
3.4b) and drug treated film (Figure 3.4c) mucosal treatments  following 6 hours of 
permeation studies displayed no noticeable histomorphological changes that were 
indicative of tissue damage. The basal cell layer (Figure 3.4d) appeared intact and 
darkly stained in H&E reflecting their greater mitotic activity characteristic of these 
basal cells, therefore suggesting that any changes from DDI or polymers would not be 
permanent. 
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These observations were then further confirmed using TEM. TEM images allow a 
deeper investigation at a cellular level to assess any destruction of the cellular 
membranes, of individual cells, as well as to the cellular organelles that ensure proper 
functioning of these cells. Damage to the cellular membrane, destruction of the nuclear 
membrane and the nucleus, as well as cytoplasmic blebbing are all markers of necrosis 
(Zong and Thompson, 2006). TEM images can also allow for the evaluation of tight-
junctions or similar interconnections between adjacent cells, as well as the evaluation 
of intercellular spaces that can be used as a route of paracellular transport. The control 
(Figure 3.5a) displayed cells that are characteristic of normal healthy cells, with no 
signs of either apoptosis or necrosis. These images also displayed very small 
intercellular spaces and relatively closely packed cells. The placebo film treatment 
(Figure 3.5b) displayed cellular morphology similar to those of the controls, with slightly 
enlarged intercellular spaces as compared to the control samples. This increase in 
intercellular spaces could be attributed to the polymers that were incorporated into the 
design of the film.  
 
The drug loaded film treatment showed a further increase in these intercellular spaces, 
which possibly aided in the transport of the drug via the paracellular route through the 
buccal mucosa. Although there was an increase in the size of the intercellular spaces 
in the drug loaded film, the tight junctions were still intact which is indicative that the 
changes caused by the drug treatment are not permanent. Apart from the observed 
changes mentioned above, no other detrimental changes to the buccal mucosa due to 
the placebo/drug treatment were observed.  
 
Both the LM and TEM studies confirmed that there was no tissue damage or distress 
due to either placebo or drug loaded film treatment. These studies further identified a 
possible route of transport for the DDI loaded film across the buccal mucosa and also 
showed evidence that the changes observed were temporary. 
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Figure 3.4: Microphotographs of the control and treated ultra-thin buccal mucosal 
sections for light microscopy (LM): (a) untreated control, (b) placebo film, 








Figure 3.5: Microphotographs of the control and treated ultra-thin buccal mucosal 
sections for transmission electron (TEM): (a) untreated control, (b) 
placebo  film, (c) drug film. 
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3.5  MUCOADHESIVITY OF FILMS 
 
The majority of mucoadhesive polymers investigated for buccal films are hydrophilic 
(Morales and McConville, 2011). Conversely hydrophobic Eudragit® can also 
demonstrate mucoadhesiveness when used separately or together with other 
hydrophilic polymers such as chitosan (Pendekal and Tegginamat, 2012, Perumal et 
al., 2008b). Prepared formulations were subsequently tested for their mucoadhesivity, 
since a prerequisite for buccal controlled drug delivery systems is adhesion on the oral 
mucosa (Eouani et al., 2001). A maximum detachment force (MDF) of 2184 mN per 
film (Figure 3.6) seen with 1:0.25:10 is comparable to optimized buccal films (Ayensu 
et al., 2012b, Eouani et al., 2001) and buccal tablets (Boyapally et al., 2010, Cappello 
et al., 2006) published previously. This indicates that the films prepared in this study 
show potential for retention at the site of drug absorption for prolonged time periods. 
 
 
Figure 3.6: Effect of HPMC and EUD on in vitro mucoadhesivity. 
 
The effect of HPMC content on mucoadhesivity was investigated (Table 3.3). The 
decrease in MDF observed as HPMC content increased could be attributed to the 
increased intermolecular interactions possibly between the higher levels of plasticizers 
and polymers in the subsequent formulations. HPMC was selected as the hydrophilic 
polymer for the formulation based on preliminary drug-polymer interaction studies. 
Molecular mechanistic simulations as discussed later under Section 3.8.4 indicated that 
HPMC showed few electrostatic interactions with –COOH and –NH2 groups of the 
mucin potentially explaining the decrease in MDF observed  as the HPMC content 
increased from 0.25 % to 1 % (Table 3.3).  
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The effect of EUD content on mucoadhesivity was also investigated (Figure 3.6). A 
decrease in MDF was also noted as EUD content increased. EUD, a cationic polymer, 
is positively charged and could interact to some extent with the negatively charged 
mucin glycoproteins. Molecular simulations supported the level of mucoadhesivity 
observed. The quaternary ammonium groups of EUD seemed to form the much 
needed electrostatic interaction to impart mucoadhesivity to the buccal films, but the 
hydrophobic nature of EUD may have caused destabilization of H-bonding. The 
mucoadhesive interaction was reduced (1930.2 ± 137.9 to 1245.7 ± 196.1 mN) as the 
EUD content increased from 5 % to 20 % respectively. EUD being a hydrophobic 
polymer restricted the free entry of water causing less efficient chain mobility and 
physical entanglement with mucus (Perumal et al., 2008b). Work of adhesion is the 
area under the force/distance curve generated by the TA-XT2i. High coefficient of 
variance (CV) percentages for work of adhesion reflects the difficulty in accurately 
measuring the area under the curve (AUC) of the narrow peaks generated on the 
stress-strain curves. Work of adhesion and MDF values followed similar trends 
throughout. Statistical significant (p < 0.05) differences between mucoadhesion (MDF) 
values were observed between the identified 1:0.5:10 formulation and other ratios 
prepared (Table 3.3). Films had acceptable mucoadhesivity but increased polymeric 
content affected mucoadhesion negatively in the multipolymeric films. A balance needs 
to be achieved between acceptable mucoadhesivity and desired drug release.  
 




Detachment Force  
(mN) n=9 
Work of Adhesion  
(mJ) n=9 










 1:0.25:10 2184.56 ± 164.28*** 7.52 1.42 ± 0.42 29.63 
1:0.5:10 1425.00 ± 77.15N/A 5.41 1.21 ± 0.32 26.18 
1:0.75:10 1371.33 ± 79.62NS 5.81 1.02 ± 0.13 12.47 











1:0.5:5 1930.22 ± 137.87*** 7.14 1.31 ± 0.23 17.17 
1:0.5:7.5 1695.78 ± 151.96*** 8.96 1.25 ± 0.15 12.00 
1:0.5:10 1425.00 ± 77.15N/A 5.41 1.21 ± 0.32 26.18 
1:0.5:15 1253.67 ± 134.62* 10.74 0.99 ± 0.17 16.82 
1:0.5:20 1245.67 ± 196.05* 15.74 1.04 ± 0.33 31.88 
Statistical significance compared to 1:0.5:10 - *** p < 0.001; ** p 0.001 to 0.01; * p 0.01 to 0.05;  




       80 
 
Published Paper Chapter Three 
 
3.6  MECHANICAL TESTING 
 
The mechanical strength of films reflects their ability to withstand mechanical damage 
during production, handling and application (Yoo et al., 2006). It was therefore 
necessary to assess the mechanical properties of the DDI monolayered multipolymeric 
films (Table 3.4). The investigated mechanical properties together represent film 
abrasion resistance, ductility and stiffness or elasticity. Increases in HPMC 
concentration resulted in increased tensile strength, Young’s modulus and force 
required to rupture the films (Table 3.4). This would lead to improved abrasion 
resistance making films less prone to breakage and more durable to handle.  The effect 
of EUD on mechanical properties was investigated. Overall improved mechanical 
properties were noted for films as the EUD content increased from 5 % to 20 %. In this 
series film elongation increased up until 1:0.5:10 (69.54 ± 7.77 %) then decreased as 
polymer content further increased in 1:0.5:15 and 1:0.5:20 (54.68 ± 0.49 % and 45.36 ± 
6.47 %). This decrease could be attributed to the increased stiffness and thickness 
resulting in tougher films. These films were rigid and could cause discomfort when 
being administered into the buccal cavity. Interestingly, the tensile strength increased 
for films with increasing amounts of HPMC, whereas the opposite was noted for films 
containing increasing amounts of EUD. A tensile strength of 0.698 N/mm2 compares 
favourably to previously produced buccal formulations (El-Kamel et al., 2007, Shidhaye 
et al., 2008, Sievens-Figueroa et al., 2012). Polymers selected and the concentration in 
the buccal formulations affect all mechanical properties. It is clear that films should 
have sufficient tensile strength to withstand necessary handling yet, be flexible enough 
to ensure patient comfort. It is for this reason that optimal polymeric blends need to be 
identified.  
 





























 1:0.25:10 2.62 ± 0.60 0.2733 ±0.051*** 0.10 ± 0.04 53.75 ± 15.61 41.27 ± 3.89 
1:0.5:10 6.69 ± 0.39 0.6976 ± 0.064N/A 0.23 ± 0.05 69.54 ± 7.77 111.70 ± 12.98 
1:0.75:10 11.90 ± 0.40 0.7288 ± 0.057NS 0.36 ± 0.03 57.41 ± 2.18 99.46 ± 17.26 










 1:0.5:5 5.46 ± 0.68 2.5545 ± 0.144
*** 1.13 ± 0.17 25.20 ± 2.90 42.71 ± 7.74 
1:0.5:7.5 5.42 ± 0.86 1.1387 ± 0.097*** 0.53 ± 0.04 38.02 ± 4.75 57.66 ± 13.04 
1:0.5:10 6.69 ± 0.39 0.6976 ± 0.064N/A 0.23 ± 0.05 69.54 ± 7.77 111.70 ± 12.98 
1:0.5:15 25.43 ± 0.66 0.6315 ± 0.029NS 0.43 ± 0.04 54.68 ± 0.49 187.58 ± 15.54 
1:0.5:20 27.75 ± 1.25 0.4358 ± 0.007*** 0.50 ± 0.09 45.36 ± 6.47 279.89 ± 33.32 
Statistical significance compared to 1:0.5:10 - *** p < 0.001; ** p 0.001 to 0.01; * p 0.01 to 0.05;  
NS p > 0.05; N/A – Non-applicable. 
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3.7  SURFACE PH 
 
The surface pH of buccal polymeric films is an important characteristic to evaluate.  In 
vivo studies by Bottenberg et al. (1991) demonstrated that fluctuations in pH beyond 
the normal range of saliva (pH 5.8-7) may cause local irritation to the buccal mucosa. A 
minimal decrease of 0.17 in pH, from pH 6.8-6.63 was measured in vitro over 24 hours 
for 1:1:10 films. The slight decreases in pH for films over time can be attributed to the 
availability of polymer that can ionise at PBS pH. As the film swells more polymer from 
the inner areas of the film become available to ionise. In vivo this does not pose a 
problem since the buccal environment is an open system, with a continuous production 
and flow of saliva (Cavallari et al., 2013). The pH values for all the formulations 
remained within a suitable range indicating that buccal mucosal irritation is unlikely to 
occur. These results indicate that the multipolymeric buccal films were suitable for 
buccal application owing to the acceptable pH measurements.  
 
3.8  ESTABLISHMENT OF THE POLYMERIC COMPLEXATION PROFILE AND 
 POTENTIAL IMPACT ON MUCOADHESION AND DRUG RELEASE VIA SLAS 
 
3.8.1  Molecular Mechanics Assisted Model Building and Energy Refinements 
 
Molecular mechanics energy relationship (MMER), a method for analytico-
mathematical representation of potential energy surfaces, was used to provide 
information about the contributions of valence terms, non-covalent Coulombic terms, 
and non-covalent van der Waals interactions for polymer/plasticizer/mucin interactions. 
The MMER model for potential energy factor in various molecular complexes can be 
written as: 
 
Emolecule/complex = V∑ = Vb + Vθ + Vφ + Vij + Vhb + Vel                 ...(1) 
 
where, V∑ is related to total steric energy for an optimized structure, Vb corresponds to 
bond stretching contributions (reference values were assigned to all of a structure's 
bond lengths), Vθ denotes bond angle contributions (reference values were assigned to 
all of a structure's bond angles), Vφ represents torsional contribution arising from 
deviations from optimum dihedral angles, Vij incorporates van der Waals interactions 
due to non-bonded interatomic distances, Vhb symbolizes hydrogen-bond energy 
function and Vel stands for electrostatic energy. 
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In addition, the total potential energy deviation, ΔETotal, was calculated as the difference 
between the total potential energy of the complex system and the sum of the potential 
energies of isolated individual molecules, as follows:  
 
ΔETotal(A/B) = E Total(A/B) – [ETotal(A) + ETotal(B)]                 ...(2) 
 
The molecular stability can then be estimated by comparing the total potential energies 
of the isolated and complexed systems. If the total potential energy of complex is 
smaller than the sum of the potential energies of isolated individual molecules in the 
same conformation, the complexed form is more stable and its formation is favoured 
(Yu et al., 2008). 
 
Table 3.5: Inherent energy attributes representing the molecular assemblies modelled 
using static lattice atomistic simulations in vacuum. 
Molecular complex ΔEa (V∑)b ΔE (Vb)c ΔE (Vθ)d ΔE (Vφ)e ΔE (Vij)f ΔE (Vhb)g ΔE (Vel)h 
HPMC-GLY -13.259 i 0.202 j 1.330 5.852 -18.225 -2.414 0.000 
EUD-TEC -21.886 0.267 3.766 0.219 -25.849 -0.268 -0.019 
HPMC-EUD -9.025 -0.463 -0.720 13.059 -19.207 -0.271 -1.420 
EUD-TEC/HPMC-GLY -52.943 0.294 5.181 7.838 -62.297 -3.504 -0.45 
HPMC-MUC -31.073 0.075 0.534 6.798 -35.727 -0.502 -2.249 
EUD-MUC -80.275 -0.177 3.011 0.842 -25.097 0.180 -59.033 
HPMC-MUC-EUD -65.011 -1.054 -6.788 24.282 -45.795 -0.658 -34.994 
a ΔE(A/B) = E (A/B) – [E (A) + E (B)]. 
b Total steric energy for an optimized structure. 
c Bond stretching contributions. 
d Bond angle contributions. 
e Torsional contribution arising from deviations from optimum dihedral angles. 
f Van der Waals interactions. 
g Hydrogen-bond energy function. 
h Electrostatic energy. 
i Values inked green depicts the structure stabilizing contribution. 
j Values inked red depicts the structure destabilizing contribution.    
 
3.8.2  Effect of the Incorporation of Plasticizer on the Individual Polymer’s 
 Performance 
 
EHPMC = 49.713V∑ = 2.089Vb + 18.821Vθ + 22.360Vφ + 6.776Vij - 0.335Vhb            …(3) 
EGLY = 2.863V∑ = 0.046Vb + 0.269Vθ + 2.123Vφ + 0.437Vij - 0.013Vhb             …(4) 
EHPMC-GLY = 39.317V∑ = 2.337Vb + 20.420Vθ + 30.335Vφ - 11.012Vij - 2.762Vhb      …(5) 
EEUD = 43.885V∑ = 5.002Vb + 21.451Vθ + 8.255Vφ + 2.398Vij + 6.777Vel             …(6) 
ETEC = 3.913V∑ = 0.497Vb + 2.524Vθ + 1.206Vφ - 0.105Vij - 0.209Vhb             …(7) 
EEUD-TEC = 25.912V∑ = 5.766Vb + 27.741Vθ + 9.680Vφ - 23.556Vij - 0.477Vhb + 6.758Vel   …(8) 
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The plasticization and filler effects of GLY and TEC w.r.t. HPMC and EUD are depicted 
in equations 3-5 and equations 6-8, respectively. Both the plasticized complexes, 
HPMC-GLY and EUD-TEC, were energetically stable with negative energy of formation 
(∆E) values of ≈13kcal/mol and ≈22kcal/mol, respectively, justifying the selection of 
plasticizers for the respective polymers for the film formation and performance. 
 
In case of HPMC-GLY, glycerine formed a well-connected H-bonded molecular 
complex with HPMC as shown in Figure 3.7a with a space-filling ability to 
accommodate within the van der Waals space of HPMC molecule which is 
strengthened by the stabilization of Vij and Vhb (Table 3.5). With a closer look at the 
HPMC-GLY complex, one can assume that one glycerine molecule can additionally 
form an “intermolecular-bridge” between two adjacent HPMC molecules inducing an 
“adjacent chain-sliding phenomenon” resulting in an increase in elasticity. Interestingly, 
introduction of glycerine to the HPMC led to an increase (destabilization) in Vφ due to 
the torsional constraints experienced by the polymer which in turn was due to the filling 
of the intramolecular-space providing the much needed alignment and distribution of 
polysaccharide side-chains. On another note, the H-bonding may however decrease 
the accessibility of HPMC functional groups as discussed later in this paper. 
 
Unlike HPMC-GLY, EUD-TEC was characterized by the absence of H-bonding at all 
modelling poses tested (data not shown), which may be due to different polarities of the 
complexing molecules. Additionally, the space-filling appeared more intermolecular 
because of the size of the TEC molecule w.r.t. EUD modelled which is evident from 
more stabilized Vij. Furthermore, as the filling was intermolecular; the torsional strain 
was much reduced as compared to HPMC-GLY (Vφ values in Table 3.5). These two 
reasons made EUD-TEC more stable than HPMC-GLY. As evident from Figure 3.7b, 
the EUD-EUD interpolymeric interaction appeared less likely because of the presence 
of plasticizer molecules between the adjacent polymeric chains which may further lead 
to increased elasticity or decreased rigidity of the EUD-component of the films 
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Figure 3.7:  Visualization of geometrical preferences of (a) HPMC-GLY: HPMC 
(standard colours) in molecular complexation with GLY (yellow rendering); 
and (b)  EUD-TEC: EUD (standard colours) in molecular complexation 
with TEC (violet rendering), after molecular simulations in vacuum. Colour 
codes for HPMC and EUD tube rendering: C (cyan), O (red), H (white), 
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3.8.3  HPMC-EUD Co-blending and Co-plasticization 
 
EHPMC-EUD = 84.573V∑ = 6.628Vb + 39.552Vθ + 43.674Vφ - 10.033Vij - 0.606Vhb + 5.357Vel              …(9) 
EEUD-TEC/HPMC-GLY = 47.431V∑ = 7.928Vb + 48.246Vθ + 41.782Vφ - 52.791Vij - 4.061Vhb + 6.327Vel  …(10) 
 
The films were fabricated using a unique blend of two polymers, with their respective 
plasticizers, in a binary-solvent system. To simulate the fabrication conditions; the 
polymers were modelled together along with their respective plasticizers forming a 
quadra-molecular system with HPMC-GLY/EUD-TEC: co-blended-co-plasticized 
polymeric architecture (BPPA). A binary blend system sans plasticizers was also 
modelled to elucidate the compatibility of the two polymers. 
 
From equation 9 and Table 3.5; it can be deduced that the polymers formed a 
stabilized geometrically and energetically stable system with all the bonding (Vb and Vθ) 
and non-bonding (Vij,Vhb, and Vel) interaction energies except Vφ. The HPMC-EUD 
molecular complex failed to demonstrate an H-bonded system with all the conformation 
poses tried (Figure 3.8a and 3.8b). Furthermore, the total energy of stabilization, 
∆E(Ve) recorded as ≈-9kcal/mol, was too low to justify an efficient blending. However, 
an intramolecular EUD H-bonding was reported in the binary mixture which may be due 
to the torsional constraints caused by the presence of HPMC which was further proven 
by the instability caused by Vφ (Figure 3.8b). 
 
The HPMC-GLY/EUD-TEC quadra-molecular system is depicted in Figure 3.8c where 
a well-connected intermolecular architecture is evident by the presence of H-bonding 
involving HPMC-GLY-EUD linked structure. Additionally; the TEC molecule was well-
fitted into the intramolecular space of EUD against the intermolecular space in case of 
EUD-TEC discussed in the previous section. Now this well-fitted and well-connected 
structure presented the “standard pattern of energy stabilization” wherein all the 
bonding interactions (Vb, Vφ, and Vθ) were destabilized and the non-bonding (Vij,Vhb, 
and Vel) ones were stabilized. Numerically, the total energy of stabilization, ∆E(Ve) = -
52.943, for HPMC-GLY/EUD-TEC was ≈6 times that of HPMC-EUD justifying the 
“novel co-blending-co-plasticizing strategy” of preparing buccal films. 
 
The drug release profile of the developed buccal films in this study can be explained 
molecular mechanistically taking the geometrical stabilization of the components in 
consideration. As explained previously under Section 3.2; an increase and decrease in 
drug release was observed with an increase in concentration of HPMC and EUD, 
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respectively. We hereby hypothesize that the component stabilizing a vacuum system 
(non-aqueous system) and an aqueous system would lead to a respective increase in 
hydrophobicity and hydrophilicity of the matrix. Convincingly, the presence of EUD-TEC 
increased the stability of the films (Equations 5 and 8; Table 3.5) leading to slower 
release of the drug as there would be less tendency of the stabilized system to undergo 
a change in terms of chain relaxation (release via diffusion) or degradation (release via 
erosion). Correspondingly, the comparatively higher concentration of HPMC-GLY will 
make the quadra-molecular architecture less stable (Equations 5 and 8; Table 3.5) in 
vacuum leading to an increase in hydrophilicity and chain relaxation or degradation – 





Figure 3.8:  Visualization of geometrical preferences of (a) HPMC-EUD: HPMC (tube 
rendering) in molecular complexation with EUD (stick rendering) with no 
H-bonding; and (b) HPMC-EUD: HPMC (tube rendering) in molecular 
complexation with EUD (stick rendering) with intramolecular H-bonding; 
and (c) HPMC-GLY/EUD-TEC: HPMC-GLY in molecular complexation 
with EUD-TEC, after molecular simulations in vacuum. Colour codes for 
HPMC and EUD: C (cyan), O (red), H (white), and P (yellow). GLY and 
TEC molecules  are shown in yellow and purple colour coding, 
respectively. 
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3.8.4  Effect of Component Polymers on the Mucoadhesivity of Buccal Films 
 
EMUC = -166.812V∑ = 5.474Vb + 70.351Vθ + 55.173Vφ - 29.066Vij - 7.096Vhb - 261.649Vel                       …(11) 
EHPMC-MUC = -148.172V∑ = 7.638Vb + 89.706Vθ + 84.331Vφ - 58.017Vij - 7.933Vhb - 263.898Vel       …(12) 
EEUD-MUC = -203.202V∑ = 10.299Vb + 94.813Vθ + 64.270Vφ - 51.765Vij - 6.916Vhb - 313.905Vel       …(13) 
EHPMC-MUC-EUD = -138.225V∑ = 11.511Vb + 103.835Vθ + 110.07Vφ - 65.687Vij - 8.089Vhb - 289.866Vel  …(14) 
 
In the present molecular mechanics simulations; a standard muco-platform was 
employed wherein glycosylated mucopeptide was modelled with EUD and HPMC 
individually and in combination (Murphy et al., 2012, Ndesendo et al., 2011). HPMC, 
though hydrophilic, is a non-ionic polymer with hydroxyl- and carboxymethyl-
functionalities in the structure whereas EUD is a cationic polymer with quaternary 
ammonium groups capable of forming electrostatic interactions with the mucin. 
Referring to ∆E values in Table 3.5; HPMC-MUC and EUD-MUC were stabilized by ≈-
31kcal/mol and ≈-80kcal/mol, respectively, with non-bonding interaction playing the 
major part. The neutral nature of HPMC showed few electrostatic interactions with 
close proximity of –OH groups of HPMC to the –COOH and –NH2 groups of MUC. 
However, the HPMC fitted well in the steric environment created by the van der Waals 
radii of MUC resulting in a geometrical stabilization [∆E(Vij)≈-25kcal/mol] (Figure 3.9a). 
The quaternary ammonium groups of EUD seemed to form the much needed 
electrostatic interactions to impart mucoadhesivity to the buccal films. This electrostatic 
stabilization [∆E(Vel)≈-59kcal/mol] was affected by the interaction of –NH3+ functionality 
of EUD with the –COOH functionality of MUC (Figure 3.9b). The hydrophobic nature of 
EUD may have caused the destabilization of H-bonding energy by 0.18kcal/mol. In 
case of HPMC-MUC-EUD; the value of ΔE of stabilization for HPMC-MUC-EUD 
[∆E(V∑)≈-65kcal/mol] lied between that of HPMC-MUC and EUD-MUC validating the 
molecular modelling approach employed in this study (Table 3.5). Interestingly, the 
stabilized and destabilized energy terms were alike in case of HPMC-EUD and HPMC-
MUC-EUD with all the bonding and non-bonding interaction terms except Vφ were 
lowered (and stabilized) during the formation of bimolecular and trimolecular 
assemblies, further validating the accuracy and appropriateness of the computational 
method applied. A high numerical decrease (and hence stabilization) in the van der 
Waals forces represented by Vij  [∆E(Vij)≈-45kcal/mol] confirms the better fit of HPMC-
EUD combination with MUC as compared to the individual polymers – hence justifying 
the use of HPMC-EUD as a blend for the formulation of the buccal films. Predictably; 
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an increase in HPMC concentration may lead to a comparative increase in HPMC:EUD 
ratio which may further lead to a decrease in mucoadhesion as mentioned in the 
experimental finding under Section 3.5. 
 
The above molecular mechanistic studies therefore provide useful quantitative 
information to simultaneously predict the stability of polymeric and plasticizer blends 
film formulation and to also identify the potential mechanisms for the observed drug 
release and mucoadhesion shown previously in Sections 3.2 and 3.5. 
Figure 3.9:  Visualization of geometrical preferences of (a) HPMC-MUC: HPMC (tube 
rendering) in molecular complexation with MUC (dot rendering); (b) EUD-
MUC: EUD (tube rendering) in molecular complexation with MUC (dot 
rendering); and (c) HPMC-MUC-EUD: MUC (dot rendering) in molecular 
complexation with HPMC (tube rendering) and EUD (ball-and-tube 
rendering), after molecular simulations in vacuum. Colour codes for 
HPMC and EUD: C (cyan), O (red), H (white), and P (yellow). Secondary 
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4.0  CONCLUSIONS 
 
The aim of this study was to formulate and characterize monolayered mucoadhesive 
multipolymeric films comprising of various ratios of co-blended polymers for buccal 
delivery of DDI. Films containing DDI were successfully prepared with HPMC and EUD 
by a simplified solvent casting/evaporation technique that eliminated the need for 
homogenization and cooling, carcinogenic solvents and additional emulsifiers. Drug 
content was uniform and within required specifications. Controlled release of DDI from 
MMFs could be obtained by modifying the ratios of HPMC and EUD. Formulations 
exhibiting desired controlled drug release and drug content uniformity had acceptable 
mechanical strength and mucoadhesivity.  The buccal permeability potential of DDI 
from polymeric films was successfully demonstrated for the first time and 
histomorphological studies confirmed no buccal tissue damage or distress due to drug 
loaded MMFs. Static lattice atomistic simulations (SLAS) provided a mechanistic 
understanding of the molecular interactions involved in film formation and confirmed 
the corroboration of the in silico and in vitro mucoadhesive and drug release 
experimental data. SLAS further justified the “novel co-blending-co-plasticizing 
strategy” of preparing buccal films. The data obtained in the study demonstrated for the 
first time the potential of buccal polymeric films to serve as platforms for delivery of 
DDI. These extensive physico-mechanical and molecular atomistic studies have 
confirmed the use of MMFs containing DDI, HPMC and EUD as a potential buccal drug 
delivery system to enhance patient therapy. They further serve as a platform for future 
studies to statistically optimize the formulations for simultaneous enhancement of drug 
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4.1  INTRODUCTION 
 
The following manuscript was submitted to an international ISI journal from data 
generated during this study: 
 
Jones, E., Ojewole, E., Kalhapure, R., Govender, T., 2013. In vitro comparative 
evaluation of monolayered multipolymeric films embedded with didanosine-loaded solid 
lipid nanoparticles: A potential buccal drug delivery system for ARV therapy. Drug 
Development and Industrial Pharmacy, SUBMITTED MANUSCRIPT. Reference 
Number: LDDI-2013-0624. 
 
Ms E. Jones contributed to the design of the project and developed suitable methods 
for preparation of DDI SLNs for the 1st time and undertook their characterisation. 
Furthermore, she was responsible for the preparation and characterisation of 
conventional and nano-enabled polymeric films in terms of assay, in vitro drug release, 
in vitro permeations, mucoadhesivity, mechanical strength, interpretation of the data 
and writing of the overall manuscript. The remaining authors served as supervisor (T. 
Govender), co-supervisor (E. Ojewole) and postdoctoral advisor (R. Kalhapure). 
 
This chapter is presented in the required format of the journal and is the final version 
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Drug delivery via the buccal route has emerged as a promising alternative to oral drug 
delivery. Didanosine (DDI) undergoes rapid degradation in the gastrointestinal tract, 
has a short half-life and low oral bioavailability, making DDI a suitable candidate for 
buccal delivery. Recent developments in buccal drug delivery show an increased 
interest towards nano-enabled delivery systems. The advantages of buccal drug 
delivery can be combined with that of nanoparticulate delivery systems to provide a 
superior delivery system. The aim of the study was to design and evaluate the 
preparation of novel nano-enabled films for buccal delivery of DDI. Solid lipid 
nanoparticles (SLNs) were prepared via hot homogenization followed by ultrasonication 
and were characterized before being incorporated into nano-enabled multipolymeric 
monolayered films (MMFs). Glyceryl tripalmitate with Poloxamer 188 was identified as 
most suitable for preparation of DDI-loaded SLNs. SLNs with desired particle size 
(201nm), PDI (0.168) and zeta potential (-18.8mV) were incorporated into MMFs and 
characterised. Conventional and nano-enabled MMFs were prepared via solvent 
casting/evaporation using Eudragit RS100 and hydroxypropyl methylcellulose. Drug 
release from the nano-enabled films was found to be faster (56% vs 20% in 1st hour). 
Conventional MMFs exhibited higher mucoadhesion and mechanical strength than 
nano-enabled MMFs. SLNs did not adversely affect the steady state flux (71.63±13.54 
µg/cm2h vs 74.39±15.95 µg/cm2h) thereby confirming the potential transbuccal delivery 
of DDI using nano-enabled MMFs. Nano-enabled buccal films for delivery of DDI can 
be successfully prepared and these physico-mechanical studies serve as a platform for 











Antiretrovirals, Entrapment efficiency, Hydrophilic drug, Mucoadhesion, Permeation, 
Transmucosal 
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1.0  INTRODUCTION 
 
Human Immunodeficiency Virus (HIV) infection and Acquired Immune Deficiency 
Syndrome (AIDS) have remained as one of the leading causes of death worldwide, and 
is a major cause of mortality in sub-Saharan Africa1,2. While antiretrovirals (ARVs) have 
proven to be useful in the treatment and management of HIV & AIDS, several 
disadvantages and limitations currently exist with respect to drug therapy3. Many of the 
ARVs undergo extensive first pass hepatic metabolism and gastrointestinal 
degradation, which leads to reduced bioavailability. The short half-lives of several 
ARVs necessitates frequent administration of doses, thereby leading to reduced patient 
compliance4. There are concerns regarding adverse effects associated with long-term 
usage of highly active antiretroviral therapy (HAART), such as HIV associated 
lipodystrophy, central adiposity, dyslipidaemia, hyperlipidaemia, hyperglycaemia and 
insulin resistance5,6.  The major contributing factor to ARV related side effects can be 
attributed to the inadequate drug concentrations reaching the site of action, and the low 
bioavailability of several ARV drugs, necessitating the use of large doses to achieve a 
therapeutic effect. Many of the currently available tablet formulations are very large and 
pose swallowing difficulties, especially for geriatric and paediatric patients. High doses, 
complex HAART dosing regimens, physical size limitations and side effects from 
multiple drugs all contribute to reduced patient compliance7. Poor drug solubility and 
limited membrane permeability also pose formulation difficulties8. HIV, being localised 
to inaccessible compartments in the human body, such as the lymphatic system, 
central nervous system and within macrophages, results in yet another treatment 
challenge. Therapeutic drug concentrations cannot be achieved in these compartments 
by the majority of ARVs, and the necessary plasma drug concentrations fail to be 
maintained at the site of HIV localisation for the required extent of time9. 
 
The identification of new drugs and chemical modification of existing ARV drugs10, the 
design and development of novel drug delivery systems11-13 and investigation of 
alternative routes to deliver ARVs14-16 are being explored to overcome the current 
limitations associated with ARV therapy. Novel drug delivery systems (NDDS) have 
been identified as a useful tool by formulation scientists to enhance drug delivery and 
have contributed significantly in the past decade to augment various classes of drugs 
including ARVs17. Examples of novel drug delivery systems that have been explored in 
the past for ARVs include sustained release matrix tablets18 and ceramic implants11, 
while more recently liposomes19 and nanoparticles20 are receiving increased interest. 
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Along with developing NDDS for ARVs, researchers have also explored various 
alternate routes to improve drug delivery of ARVs other than the conventional oral 
route14,21-23.  
 
Drug delivery via the buccal route has recently emerged as a promising alternative to 
delivery via the oral route. Drugs can directly enter the systemic circulation, bypass 
gastrointestinal degradation and first-pass hepatic metabolism, thereby increasing 
bioavailability24. The buccal mucosa is easily accessible and more permeable than 
skin25, making this a suitable route for drug delivery in pediatrics and geriatrics. 
Formulating a drug into a controlled release, mucoadhesive buccal dosage form may 
further improve drug delivery and patient compliance26. Several ARV drugs may 
therefore benefit from delivery via the buccal route. 
 
For the buccal route, studies investigating the delivery of ARVs are limited compared to 
the transdermal route, and have focused mostly on permeability studies with ARV drug 
solutions rather than formulation studies. The majority of work thus far has focussed on 
in vitro drug permeability studies using only drug solutions of zalcitabine23,27, 
didanosine16,28 and tenofovir16. The only available published papers on buccal 
polymeric dosage forms containing ARVs are of zidovudine polymeric patches 
produced by Reddy et al.29 and of didanosine monolayered multipolymeric films 
(MMFs) recently reported by our group30. ARV buccal drug delivery systems have not 
been comprehensively investigated or characterised, and a clear need still exists for 
formulation optimization in this field. Didanosine (DDI) is a nucleoside reverse 
transcriptase inhibitor (NRTI), acts by competitive inhibition of HIV-1 reverse 
transcriptase, and can also be incorporated into the growing viral DNA chain to cause 
chain termination31. DDI is currently faced with many limitations. Rapid drug 
degradation of DDI in the gastrointestinal tract due to acid hydrolysis, together with the 
need for repetitive dosing, its short half-life, low oral bioavailability and dose-related 
toxicity, make DDI a suitable model ARV drug for incorporation into a novel buccal 
delivery system. 
 
Recent developments in the field of buccal drug delivery show an increased interest 
towards nano-enabled buccal drug delivery systems32-34. The advantages of buccal 
drug delivery can be combined with that of the nanoparticulate drug delivery systems to 
provide a superior drug delivery system in terms of enhanced bioavailability35 and drug 
targeting depending on the nanoparticulate system involved8,36. A very limited number 
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of studies have been done to date in this emerging field with a majority of these studies 
focussing on using hydrogels34 or multilayered polymeric patches35,37 as delivery 
vehicles, and delivery of nanosized drug particles38 or therapeutic proteins32,33. 
Antiretrovirals in a nano-enabled film for buccal drug delivery remain to be investigated 
in this emerging field. Nanoparticulate systems that have been studied for 
transmucosal drug delivery include: drug nanosuspensions prepared by wet stirred 
media milling of the drug37,38, PEG-b-PLA copolymeric nanoparticles prepared by 
double emulsion solvent evaporation32 and protein-coated D,L-valine nanoparticles 
prepared by antisolvent co-precipitation33,39. A nanoparticulate system of particular 
interest is solid lipid nanoparticles (SLNs).  SLNs are prepared from lipids, which are 
solid at room temperature and surfactants or stabilizers40, in the nanometer size (< 
1000 nm) range. Advantages of SLNs over other nanoparticulate systems include: 
increased stability40, controlled drug release41, targeted drug delivery36,42 and the 
incorporation of both hydrophilic43 and lipophilic44 drugs. Furthermore, SLNs lipids are 
biocompatible and organic solvents can be avoided during manufacturing processes45. 
SLNs incorporated into buccal MMFs have not been explored in the literature for any 
drug. There is therefore a clear need to explore the use of SLNs and buccal polymeric 
films to potentiate the delivery of an ARV drug via the buccal route. Furthermore, the 
incorporation of DDI into SLNs has not been reported in the literature for any 
application or route to the best of our knowledge. Thus the identification of a 
formulation will lend itself to its application as a nanoparticulate system for numerous 
delivery routes. By incorporating the drug in the form of nanoparticles into the buccal 
film, a reduction in dose-dependent side effects can be expected, as drug targeting to 
the required site of action can be achieved using a smaller dose. The additional 
reduced cost could make DDI more therapeutically useful once more. Incorporating 
multiple ARVs into nanoparticles can be accomplished to achieve multi-drug HAART 
regimens46. 
 
The aim of the study was to design and evaluate novel nano-enabled polymeric films 
for buccal delivery of DDI as a model ARV drug. In the present study, the potential of 
SLNs entrapped into MMFs for buccal delivery of DDI has been specifically examined. 
The objectives were to identify optimal parameters for preparation of DDI loaded SLNs 
and to prepare and compare the physico-mechanical properties of nano-enabled DDI 
films with conventionally prepared DDI films. 
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2.0  MATERIALS AND METHODS 
 
2.1  MATERIALS 
 
Didanosine (DDI) was purchased from Ruland Chemistry Co., Ltd (Nanjing, China) and 
used as received. Stearic acid, glyceryl tripalmitate (GTP), yellow beeswax, theobroma 
oil, glycerol monostearate, sodium lauryl sulphate, Poloxamer 188 (P188), Tween 80, 
Span 85, Solutol® HS 15, sodium deoxycholate, hydroxypropyl methylcellulose 
(HPMC), triethyl citrate (TEC) and mucin were purchased from Sigma-Aldrich (UK) and 
used as received. Compritol® 888 ATO was obtained as a gift sample from Gattefossé, 
France. Crodamol® MM and Crodamol® CP were obtained as a gift samples from 
Croda (Pty) Ltd, South Africa. Eudragit® RS 100 (EUD) (Evonik Rohm GMBH, 
Germany) was donated by Degussa Africa (Pty) Ltd.  All other reagents used (NaCl, 
Na2HPO4, KH2PO4, NaOH, HCl, MeOH, EtOH and Glycerol) were of analytical reagent 
grade. Purified water used throughout the studies was produced in the laboratory with 
a Milli-Q purification system (Millipore Corp., USA).  
 
The formula for phosphate buffered saline (PBS) used for in vitro drug release, 
permeation and mucoadhesion studies has been reported previously30,47. 
 
2.2  METHODS 
 
2.2.1 Lipid Screening Study 
 
The lipid solubility of DDI in different lipids was estimated using adapted methods48,49. 
The drug was mixed individually with eight different lipids: Stearic acid, glyceryl 
tripalmitate, yellow beeswax, theobroma oil, Crodamol® MM (myristyl myristate), 
Crodamol® CP (cetyl palmitate), Compritol® 888 ATO (glyceryl behenate) and glycerol 
monostearate in concentrations ranging from 0.0625 to 1 % w/w. The physical mixtures 
of lipid and DDI were heated at 95 °C and agitated for 3 hours using a thermostatically 
controlled shaking water bath with a mechanical shaker platform onto which a bottle 
holder plate was positioned. The melts obtained were visually examined for 
undissolved drug. The samples were left at room temperature (25 °C) until 
solidification. Full solubilisation was deemed when clear molten liquids were obtained 
and no precipitation upon solidification was noted.  
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Further lipid screening studies consisted of preparation of drug-free preformulations 
using methods described under preparation of SLNs, and measuring the pH of the 
resulting mixture to evaluate for possible incompatibilities with DDI due to the acid-
labile nature of the drug. Results were represented by the mean ± SD of three replicate 
measurements. 
 
2.2.2  Preparation of SLNs 
 
SLNs were prepared using a hot homogenization process followed by 
ultrasonication42,48. Briefly, the solid lipid (5 % w/v) was heated 5-10 °C above its 
melting point to 80 °C, and then added to a mixture of surfactants (1.6 % w/v) and 
water, previously heated at the same temperature. A pre-emulsion was obtained upon 
homogenization at 12000 rpm, for 4 min, using a high-speed homogenizer (Ultra Turrax 
T25, IKA, Germany) whilst maintaining the temperature at 80 °C during the 
homogenization step. The resulting pre-emulsion (25 mL) was ultrasonified using a 
probe sonicator (Omni Sonic Ruptor 400, Omni Inc., USA) with a 4 mm diameter probe 
and by applying a 40 % amplitude for 10 min, which lead to droplet breakage by 
acoustic cavitation, and subsequent formation of nanoparticles50. The obtained o/w 
nanoemulsion was cooled in an ice bath to room temperature to form SLNs. For drug-
loaded SLNs, the drug (0.4 to 2 % w/v) was added to the aqueous phase before 
heating and addition to the lipid phase. Samples were stored at 4 °C for further 
analyses.  
 
2.2.3  Characterisation of SLNs 
 
2.2.3.1  Particle Size and Zeta Potential Measurements 
 
The mean particle size diameter (Z-average) and polydispersity index (PDI) as a 
measure of the width of particle size distribution, were measured via photon correlation 
spectroscopy (PCS) using a Malvern Zetasizer Nano ZS (Malvern Instruments, UK). 
Prior to particle size analysis the SLN dispersions were diluted with purified water 
(1:30) to obtain the required opalescence and count rates (50-200 Kcps)44. All 
measurements were performed in triplicate and results are reported as the mean and 
standard deviation of the three replicates. 
 
The surface charge was measured by determining the zeta potential (ZP) of SLN 
dispersions after samples were suitably diluted with purified water, the conductivity of 
which was adjusted to 50 μS/cm.  
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2.2.3.2  Morphology of SLNs 
 
The shape of SLN formulations were observed under a transmission electron 
microscope (TEM) to study the morphology of the resulting SLNs. SLN dispersions 
were diluted with purified water (1:3), mounted on copper grids and air dried at room 
temperature. The samples were then stained for 30 seconds using 4 % uranyl acetate 
before viewing under a TEM (JOEL1010, Japan). 
 
2.2.3.3  Entrapment Efficiency  
 
SLN dispersions (± 25 mL) were made up to 100 mL with purified water in a volumetric 
flask prior to determination of drug entrapment efficiency (EE). A volume of 1 mL of per 
SLN formulation was ultrafiltered using Amicon® Ultra 4 centrifugal filter units (Merck 
Millipore, Germany) equipped with a 10 kDa membrane filter in a centrifuge at 5000 g 
for 15 min. The EE was calculated by comparing the amount of unencapsulated DDI in 
the ultrafiltrate versus, the total amount of drug added to the formulation. Samples of 
the ultra filtrate were appropriately diluted with purified water before quantification via a 
validated UV method at a wavelength of 250 nm (Shimadzu 1650 PC, Japan). All 
determinations were performed in triplicate. 
 
The amount of encapsulated DDI was calculated using the equation below. The free 
amount of DDI remaining in the aqueous phase following separation via ultrafiltration 
was subtracted from the total amount of DDI used to prepare the formulation51. 
 
100
DDI) of amount (Total
DDI) of amount (Free DDI) of amount (Total% EE ×−=
 
 
2.2.2  Preparation of SLN Loaded Buccal Films 
 
Buccal films were prepared as previously described30. Briefly, monolayered 
multipolymeric films (MMFs) comprising of HPMC and EUD were prepared by 
dissolving specified quantities (Table 4.1) of EUD and TEC as its plasticizer together 
with HPMC and glycerol (GLY) as its plasticizer in 50 mL methanol. To this polymeric 
mixture 25 mL of purified water and either 25 mL of DDI in purified water for 
conventional drug-loaded films (CD) or 25 mL DDI SLN nano-emulsion for nano-
enabled drug-loaded films (ND) was added and mixed until homogenous suspensions 
formed.   
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An amount of the polymeric casting mixture, equivalent to 20 mg of DDI, was syringed 
into each 6 cm2 well of the silicone moulded tray (SMT) containing Teflon coated 
Perspex inserts52. The mixtures were allowed to dry in an oven (Series 2000, Scientific, 
SA) at 43 °C for approximately 24 h, until the solvent had evaporated and constant film 
weight was achieved. Films were removed from the moulds and stored using wax 
paper and foil in a desiccator at room temperature (23 °C) up to a maximum of three 
months until further use.  
 
Conventional drug free films (Conventional Placebo / CP) and drug free SLN films 
(Nano-enabled Placebo / NP) were prepared as described above by omitting the drug 
from the 25 mL purified water or during preparation of SLNs, respectively. 
 
Table 4.1: Composition of the buccal film formulations. 





















CP Conventional Drug Free 10 3 0.5 0.15 - 100 2 - 
CD Conventional  Drug Loaded 10 3 0.5 0.15 - 100 2 20 
NP Nano-enabled Drug Free 5 1.5 0.25 0.075 25 100 4 - 
ND Nano-enabled Drug Loaded 5 1.5 0.25 0.075 25 100 4 20* 
*Include entrapped and unentrapped drug.  
 
2.2.3 Characterisation of Films 
 
2.2.3.1  Weight and Thickness Uniformity 
 
Three films per batch were randomly selected and individually weighed using an 
electronic balance (Metller Toledo AB204-S., Switzerland) and measured in five 
different locations (centre and four corners) using a digital micrometer (Mitutoyo Co., 
Japan), respectively.  
 
2.2.3.2  Assay of Films 
 
The assay solvent consisted of 80 % ethanol in water. A 6 cm2 film as a unit from the 
SMT was dissolved in approximately 40 mL of the assay solvent in a 100 mL 
volumetric flask before making up to volume with the same assay solvent. Following 
appropriate dilution (1 in 10), the drug content in the samples was quantified using a 
validated UV spectrophotometric method at a wavelength of 250 nm (Shimadzu 1650 
PC, Japan). All assays were performed in triplicate. 
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2.2.3.3  In Vitro Drug Release 
 
A modified BP2009 Type II paddle dissolution test apparatus (Erweka DTR-6., 
Germany) was employed to determine in vitro drug release of the buccal films30,53. The 
dissolution studies were carried out in 900 mL PBS adjusted to pH 6.8 and maintained 
at 37 ± 0.5 °C; with a stirring speed of 50 rpm. The film size required for dose delivery 
(6 cm2) was used. The film was placed into a stainless steel wire mesh basket and 
dropped into the dissolution vessel at the start of the experiment. A wire mesh basket 
was used, instead of attaching a film to a glass slide with adhesives as commonly 
reported54, in an attempt to limit interference with drug release. Aliquots of 6 mL 
samples from the dissolution medium were collected at predetermined time intervals of 
15, 30, 45, 60, 90, 120, 150, 180, 240, 300 and 360 minutes using a syringe and in line 
filtration (0.45 μm).  An equal volume (6 mL) of fresh PBS was replaced into each 
dissolution vessel, to ensure that a constant volume of dissolution medium was 
maintained throughout the duration of the study. The filtered samples were quantified 
for drug using a UV spectrophotometer (Shimadzu 1650 PC, Japan) at a wavelength of 
250 nm. The results are represented as the average of three films. 
 
2.2.3.4  In Vitro Permeation 
 
In vitro permeation experiments were performed on the prepared MMFs as 
reported28,55,56. Porcine buccal mucosa was used as a biological membrane for these 
experiments due to the many similarities to the human buccal mucosa as highlighted 
by Shojaei57 and Sudhakar et al.58. 
 
Briefly, porcine buccal mucosa was excised from domestic pigs (30-40 kg), the excess 
adipose and connective tissue was removed using surgical scissors, and samples were 
wrapped in foil before being snap-frozen in liquid nitrogen and stored at – 85 °C in a 
biofreezer for up to 3 months59. 
 
On the day of the experiments, frozen buccal mucosal specimens were allowed to thaw 
and equilibrate in PBS pH 7.4 to regain elasticity temporarily lost while frozen. Franz 
diffusion cells (PermeGear, Inc, USA) each with a diffusional area of 0.786 cm2 were 
used for the in vitro permeation experiments. The buccal mucosa and polymeric film 
were mounted between the donor and receptor compartments using two membrane 
holders. Two millilitres PBS at pH 6.8, simulating human saliva47, was placed on the 
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film in the donor compartment while the receptor compartment contained 27 mL PBS 
pH 7.4 maintained at 37 °C (by means of a surrounding jacket) and stirred constantly.  
 
At predetermined time intervals over 360 minutes, samples (27 mL) were taken from 
the receptor compartments and replaced by drug-free PBS. Similar to dissolution 
studies; samples were immediately filtered through a 0.45 μm membrane filter and the 
drug content was quantified using a UV spectrophotometer (Shimadzu 1650 PC, 
Japan) at a wavelength of 250 nm.  A minimum of three replicates were performed. 
 
The cumulative amount of DDI permeated per unit surface area was plotted versus 
time. The steady state flux (Jss) across the mucosal membrane was determined from 
the linear portion of the permeation graph by linear regression analysis (Microsoft Excel 
2010).  The permeability coefficient (P) was calculated using the following equation27: P 
= (dQ/dt)/A x Cd = Jss/Cd. Where dQ/dt is the cumulative amount (Q) of DDI which 
permeated into the receptor compartment per unit time (t), A is the active cross-
sectional area (0.786 cm2) available for diffusion and Cd is the drug concentration in the 
donor compartment. 
 
2.2.3.5  Mucoadhesivity of Films 
 
The mucoadhesive properties were studied using methods adapted from Ayensu et 
al.60 and Perumal et al.61 as previously reported by us30. Briefly, film samples (n=3),  
free from physical imperfections were individually attached to removable 2x3 cm 
aluminium probes using double sided adhesive tape. The probes were attached to the 
upper movable arm of the TA.XT2i Texture Analyser (Stable Micro Systems, UK). A 
Petri-dish containing 10 % w/v solidified gelatin gel, simulating the buccal mucosa, was 
clamped into place on the stationary platform of the TA.XT2i60 and  2 mL of 30 % w/v 
mucin at 37 °C was spread on the surface of the gelatin immediately prior to testing61. 
The film was allowed to hydrate for 120 seconds in PBS pH 6.8 before being brought 
into contact with the mucin covered gelatin. The film was held in place with a force of 
100 grams for 60 seconds before the mobile arm was raised. The mucoadhesive 
performance of the samples was determined by measuring the Maximum Detachment 
Force (MDF) (mN) and Work (mJ). The MDF represents the maximum force required to 
detach the film from the mucin covered gelatin. The area under the force/distance 
curve was also determined to represent the work required for detachment of the two 
systems (mucin/polymeric film)62. A minimum of nine replicate determinations were 
performed. 
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2.2.3.6  Mechanical Testing  
 
Mechanical properties of the films were studied using methods previously reported by 
us30, with the aid of a TA.XT2i Texture Analyser (Stable Micro Systems, UK). Briefly, 
individual film samples (n=5), were held between the grips (TA-96). A sheet of Teflon 
was attached to the surface of the grips via double-sided tape to prevent the film being 
cut by the grooves of the grips. During measurement, the film was pulled by the top 
grip at a rate of 1 mm/s to a distance of 150 mm before returning to the starting point. 
Data acquisition was terminated when the film ruptured completely. The force and 
elongation were measured when the films broke. 
 
The tensile strength, percent elongation, film toughness and Young’s modulus were 
used as indicators of the mechanical properties of the films. Mechanical properties of 




length in Increase(%) break at Elongation
(mm) film of Thickness (mm) Width






Young’s modulus was determined from the slope of the initial linear portion of the 
stress-strain plots generated with the Texture Expert™ software. The area under the 
force-time plots were used as an indication of film toughness32. 
 
A rupture test was also performed to assess the mechanical film properties. A film 
support rig with an exposed area of 0.786 cm2 was attached to the heavy duty platform 
of the TA.XT2i Texture Analyser. Individual film samples (n=3) were clamped between 
the film support rig before passing a 5 mm stainless steel ball probe through a sample 
at 1 mm/s in compression mode. The force (N) required to rupture the film was 
measured38. 
 
2.2.4  Statistical Analysis 
 
All calculations were undertaken with Microsoft Excel ® (Microsoft Office 2010, USA). A 
minimum of three replicates were performed and results are expressed as mean ± SD. 
Statistical analysis of data were performed using GraphPad Prism, Version 5 
(GraphPad Software., Inc, USA). One-way ANOVA followed by Dunnett’s multiple 
comparisons test or a two-tailed unpaired t-test was used to determine statistical 
significance where appropriate. P-values of p < 0.05 were considered significant.  
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3.0  RESULTS AND DISCUSSION 
 
3.1  LIPID SCREENING STUDY 
 
The solubility of the drug in melted lipid is a critical factor that determines the degree of 
drug loading in the solid lipid64. For the purpose of this study freely available lipids, 
commonly used in the preparation of SLNs, were screened for suitability for use with 
DDI (Table 4.2). The results of the lipid solubility studies indicated that DDI had the 
best solubility in stearic acid (SA) and appeared to be most suitable for the preparation 
of DDI-loaded SLNs. However, DDI is an acid labile drug and undergoes rapid 
degradation in the GIT. At acidic pH, hydrolysis of the glycosidic bond between the 
sugar and the base moieties of DDI will inactivate the drug31. For this reason 
formulations should ideally be prepared at neutral or at a slightly alkaline pH to ensure 
that drug stability is maintained. 
 
The measurements of preformulation pH values showed a substantially lower pH (4.03 
± 0.058) with stearic acid when compared to the other investigated lipids. Even though 
stearic acid showed the greatest potential for preparation of DDI SLNs in terms of drug 
solubility, the resulting low pH would preclude its use, and alternative lipids should be 
used. One cannot only select a suitable lipid for SLNs based on lipid solubility studies 
alone, physico-chemical properties and stability of the drug needs to also be 
considered. Neutral lipids such as glyceryl tripalmitate may be more suitable for an acid 
labile drug such as DDI. Studies by Teeranachaideekul and co-workers have 
highlighted the importance of examining the chemical stability of the drug in the lipid 
matrix during preformulation studies and concluded that the chemical stability of the 
drug is heavily dependent on the  lipid type65.  
 














(w/w) pH  
Stearic acid 67-72 I I I or PS PS NS 4.03 ± 0.058 
Theobroma oil 34-38 I I I I I or PS 5.47 ± 0.058 
Yellow beeswax 62-64 I I I I or PS PS 4.27 ± 0.115 
Glyceryl tripalmitate  66-68 I I I I I or PS 5.93 ± 0.115 
Myristyl myristate 39-43 I I I I I 4.80 ± 0.000 
Cetyl palmitate 54-55 I I I I I or PS 4.73 ± 0.058 
Compritol® 888 ATO 65-77 I I I I I 5.53 ± 0.058 
Glycerol monostearate 55-60 I I I I I 5.23 ± 0.058 
Key: I = Insoluble, PS = Partially soluble, NS = Nearly soluble. 
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3.2  PREPARATION OF SLNS 
 
SLNs offer numerous advantages over other nanoparticulate systems such as 
prolonged stability, controlled drug release and the ability to incorporate both 
hydrophilic and lipophilic drugs45. Although DDI have been incorporated into various 
nanoparticulate systems49,66-68, to date the preparation of DDI SLNs have not been 
reported. Kasongo et al., reported DDI-loaded nanostructured lipid carriers (NLC) 
which are prepared by mixing solid lipids with liquid lipids rather than solid lipids 
only49,51. The current study reports a hot homogenization process followed by 
ultrasonication technique for preparation of DDI SLNs and investigates the effect of 
different lipids, surfactants and drug loading on SLN characteristics. 
 
3.3  CHARACTERISATION OF SLNS 
 
3.3.1 Effect of Lipid Type 
 
The effect of different lipids on the particle size (PS), polydispersity index (PDI), zeta 
potential (ZP) and drug entrapment efficiency (EE) were evaluated (Table 4.3). The ZP, 
which is a measure of the surface charge of the particles, ranged between -16.2 mV 
and -27.3 mV, indicating that particle aggregation would be unlikely to occur20. Stearic 
acid showed the highest EE (14.48 %), but was not suitable for further investigation 
due to the low formulation pH (4.03). Stearic acid is a self-emulsifying lipid able to 
entrap more hydrophilic drug in the SLNs43 than lipids with a highly ordered crystalline 
structure69 such as cetyl palmitate (1.55 %). Glycerol monostearate displayed an EE of 
13.75 %, which is high in comparison to the lipids investigated, but posed formulation 
difficulties and had an undesirable PS and PDI. From the investigated lipids, glyceryl 
tripalmitate was identified as the most suitable lipid for preparation of DDI-loaded 
SLNs. Formulations had a near neutral pH (5.93) essential to ensure drug stability, 
small PS (198 nm), with a low PDI (0.175) indicating that the particle size distribution 
was monodisperse.  
 
Although the Poloxamer 188 (P188) is a non-ionic surfactant, the presence of 
negatively charged lipids in the formulation (e.g. stearic acid), could have contributed to 
the negative zeta potential values measured. These findings are consistent with the 
preparation of SLNs also prepared with P188 in a previous study70. 
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Table 4.3: Influence of different lipids on characteristics of SLNs. 
Lipid Type PS (nm) PDI ZP (mV) EE (%) pH 
MEAN ± SD MEAN ± SD MEAN ± SD MEAN ± SD MEAN ± SD 
Myristyl myristate 195.6 ± 13.8 0.234 ± 0.047 -24.39 ± 3.26 6.60 ± 3.16 4.80 ± 0.000 
Cetyl palmitate 201.3 ± 5.6 0.229 ± 0.050 -26.09 ± 1.51 1.55 ± 3.00 4.73 ± 0.058 
Yellow beeswax 162.5 ± 5.7 0.181 ± 0.011 -26.77 ± 1.93 11.45 ± 6.52 4.27 ± 0.115 
Glycerol monostearate 332.7 ± 93.1 0.265 ± 0.133 -20.16 ± 1.99 13.75 ± 4.45 5.23 ± 0.058 
Compritol® 888 ATO 159.0 ± 1.3 0.235 ± 0.003 -22.67 ± 0.40 6.90 ± 1.36 5.53 ± 0.058 
Theobroma oil 183.3 ± 4.8 0.192 ± 0.017 -18.10 ± 2.06 3.93 ± 3.01 5.47 ± 0.058 
Glyceryl tripalmitate 198.3 ± 0.6 0.175 ± 0.010 -16.20 ± 0.27 10.66 ± 0.95 5.93 ± 0.115 
Stearic acid 230.1 ± 3.0 0.120 ± 0.030 -27.34 ± 2.48 14.48 ± 2.60 4.03 ± 0.058 
1g Lipid + 400 mg P188 + 100mg DDI 
 
3.3.2 Effect of Surfactant Type 
 
The effect of different surfactants on PS, PDI, ZP and EE of the SLNs was evaluated 
(Table 4.4). Glyceryl tripalmitate as identified from Table 4.3 was used in this study. 
Surfactant free particles were also prepared and resulted in relatively large particle 
sizes (406.9 ± 26.2) highlighting the importance of adding adequate amounts of 
surfactant to cover the surface of the particles. Surfactants can be used to reduce the 
particle size by decreasing the interfacial tension in the aqueous phase43. Poloxamer 
188 was identified as the most suitable surfactant due to the low particle size (198 nm), 
narrow particle size distribution (PDI of 0.175) and comparatively higher EE (10.7 %) 
from amongst the surfactants investigated. Anionic surfactants such as sodium 
deoxycholate or sodium lauryl sulphate had an alkaline formulation pH (7.4 and 7.2) 
which would be ideal for DDI stability and strong negative surface charges (-24.2 mV 
and -18.7 mV) for formulation stability, yet displayed low EE (6.7 % and 3.8 %). The 
solubility of DDI in water is pH-dependent with its solubility increasing in the aqueous 
phase as the pH increases71. This pH-dependent solubility could have resulted in DDI 
being more soluble in the alkaline aqueous phase during preparation of our SLNs with 
anionic surfactants, leading to lower EE in the lipid matrix. The stability of DDI at 
different pH conditions has been reported72,73 and these studies highlighted 
pronounced drug degradation under acidic conditions. It can therefore be suggested 
that the SLNs should be prepared at a pH where the drug solubility is limited, yet at 
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Table 4.4: Influence of different surfactants on characteristics of SLNs. 
Surfactant Type PS (nm) PDI ZP (mV) EE (%) pH  
MEAN ± SD MEAN ± SD MEAN ± SD MEAN ± SD  
Span 85 212.7 ± 0.6 0.326 ± 0.054 -22.53 ± 1.68 6.63 ± 0.07 5.5 
Tween 80 224.0 ± 4.2 0.298 ± 0.010 -5.24 ± 0.89 7.99 ± 1.85 5.2 
Solutol HS 15 220.7 ± 2.4 0.263 ± 0.004 -3.49 ± 1.45 0.43 ± 0.40 5.5 
Poloxamer 188 198.3 ± 0.6 0.175 ± 0.010 -16.20 ± 0.27 10.66 ± 0.95 5.8 
Sodium deoxycholate 217.6 ± 0.6 0.257 ± 0.015 -24.20 ± 1.47 6.70 ± 5.95 7.4 
Sodium lauryl sulphate 211.0 ± 1.2 0.175 ± 0.003 -18.67 ± 3.96 3.75 ± 0.77 7.2 
1g GTP + 400mg surfactant + 100mg DDI 
 
3.3.3 Effect of Drug Loading 
 
The effect of drug amount added to SLN preparations on the particle characteristics 
was investigated and a maximum drug entrapment efficiency of 18 % was achieved at 
a drug loading of 1.2 % w/v (Table 4.5). Further increases in drug loading did not 
improve EE and this could possibly be attributed to saturation of the lipid matrix74. 
Excess drug not entrapped/associated with the SLNs prepared, were still incorporated 
into MMFs as free drug and allowed for conventional drug release and buccal 
permeation as also reported previously by another study34. 
 
In a study on saquinavir stearic acid SLNs, saturation of the lipid matrix occurred at 1 
% w/v and further increases in drug loading also did not result in higher EE74. A study 
by Ghadiri and co-workers reported contrasting results concerning increasing the drug 
amount and the resulting entrapment efficiency43. When using a microemulsion 
technique for preparation of paromomycin (hydrophilic) SLNs, the EE decreased as the 
drug amount increased. The converse was found when using a solvent diffusion 
technique for preparation of their SLNs.  
 
Table 4.5: Effect of drug loading on characteristics of SLNs. 
Drug Amount  
(mg - % w/v) 
PS (nm) PDI ZP (mV) EE (%) pH  
MEAN ± SD MEAN ± SD MEAN ± SD MEAN ± SD  
Drug Free - 0 % w/v 202.9 ± 1.0 0.183 ± 0.004 -15.10 ± 1.80 - 5.8 
100 mg - 0.4 % w/v 198.3 ± 0.6 0.175 ± 0.010 -16.20 ± 0.27 10.66 ± 0.95 5.8 
300 mg - 1.2 % w/v 196.8 ± 2.9 0.181 ± 0.018 -18.40 ± 1.40 18.06 ± 1.04 5.5 
500 mg - 2 % w/v 201.3 ± 1.9 0.168 ± 0.007 -17.83 ± 0.40 15.79 ± 0.33 5.5 
1g GTP + 400mg P188 + varying DDI 
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Incorporation of hydrophilic drugs, such as DDI, poses difficulties for incorporation into 
SLNs as demonstrated by the relatively low drug entrapment efficiency found in this 
study (< 18 %). Reported EE values for hydrophilic drugs incorporated into SLNs vary 
widely: 42 % for paromomycin43, 27 % for zidovudine75 and as low as 13 % for 
cyclosporine A76 have been reported. The main aim of this study was not to optimise 
the drug entrapment efficiency of DDI into SLNs, but the focus was rather on the 
preparation and evaluation of nano-enabled films for buccal drug delivery of DDI. 
Future studies can focus on optimizing EE specifically, by considering factors such as 
ion-pairing, polymer coating of the SLNs or investigating the effect of novel formulation 
strategies. 
 
3.3.3 Morphology of SLNs 
 
TEM images of DDI SLNs prepared using GTP (Figure 4.1) indicate that the particles 
were spheriodal in shape with smooth, nonporous surfaces. Particles were non-
aggregated, homogenously distributed and the size (± 230 nm) correlated well with size 




Figure 4.1:  TEM micrograph depicting the shape and surface morphology of the DDI 
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3.4  PREPARATION OF SLN LOADED BUCCAL FILMS 
 
Studies previously reported30 revealed the most suitable formulation variables to use in 
terms of polymeric ratios for the preparation of monolayered multipolymeric films 
(MMFs) containing polymers of opposing solubilities and DDI. For the purpose of this 
comparative study a total of four MMF formulations were prepared either being 
designated as drug-free or drug-loaded as well as being formulated with conventionally 
loaded drug or drug entrapped into nano-emulsions (Table 4.1). All films prepared via 
the different formulations were thin, flexible and their surface appeared to be fairly 
homogenous with limited entrapped air bubbles (Figure 4.2a-c). Nano-enabled drug 
loaded films (Figure 4.2d) appeared to have a similar appearance than conventional 
drug loaded films (Figure 4.2b).  
 
Drug loaded films had the highest opaqueness and interesting to note, the films 
prepared using drug-free SLNs (Figure 4.2c) were not as transparent as their 
conventional drug-free counterparts (Figure 4.2a). The polymeric/nano-emulsion 
mixtures were also completely homogenous prior to film casting and no phase 
separation occurred upon drying. Drying at 43 °C for 24 h did not pose stability 
concerns for the drug since didanosine’s thermal stability in excess of 85 °C has been 
previously established51. Nano-enabled films with acceptable appearance can therefore 
be prepared. 
 
Figure 4.2:  Digital photographs of:  (a) Conventional drug free film – CP,  
     (b) Conventional drug loaded film – CD,  
     (c) Nano-enabled drug free film – NP,  
     (d) Nano-enabled drug loaded film – ND. 
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3.4.1  Characterisation of SLN Loaded Buccal Films 
 
Physico-chemical characteristics of the MMFs are depicted in Table 4.6.  Film 
thickness was not influenced by drug loading, whereas the effect of drug loading on 
film weight was more pronounced. The lipid content of nano-emulsions contributed to 
the weight. Problems encountered with drug content uniformity in buccal films26 have 
been overcome in this study by using similar silicone moulded trays with individual 
wells for film casting as previously investigated by our group52. Drug content of films 
ranged between 92.6 % and 95.6 % with low CV values (< 5.7 %) signifying good drug 
content uniformity. All films were homogenous and had acceptable drug content 
uniformity.  
 
Table 4.6: Drug content uniformity, thickness and film weight of various film 
formulations. (Mean ± SD values; n=3). 
Type of  
Buccal Film Assay (%) Thickness (µm) Weight (mg) 
  MEAN ± SD CV % MEAN ± SD CV % MEAN ± SD CV % 
CP Conventional Drug Free - - 293.67 ± 28.02 9.54 277.09 ± 2.44 0.88 
CD Conventional  Drug Loaded30 95.62 ± 5.41 5.66 299.60 ± 25.00 8.34 293.60 ± 1.50 0.51 
NP Nano-enabled Drug Free - - 292.47 ± 24.59 8.41 328.50 ± 7.47 2.27 
ND Nano-enabled Drug Loaded 92.57 ± 1.34 1.45 297.67 ± 34.50 11.59 345.40 ± 1.97 0.56 
 
3.5.2  In Vitro Drug Release 
 
The in vitro drug release of DDI incorporated into films was investigated (Figure 4.3). A 
polymeric ratio between HPMC and EUD identified in a previous study30 known to 
exhibit sustained drug release, was used during preparation of MMFs in the current 
study. Nano-enabled MMFs released DDI at a substantially faster rate than 
conventionally loaded MMFs (Figure 4.3). The lower drug release from films prepared 
with drug solution as opposed to drug incorporated into nanoparticles, has also been 
observed previously33. Morales and co-workers postulated that when drug is added to 
the film as a solid solution, the drug molecules are completely surrounded by the 
polymeric film matrix and a higher number of drug-polymer interactions can be 
achieved, resulting in slower drug release. In our study DDI release from the nano-
enabled films was higher, with 56 % drug released in the 1st hour as opposed to 20 % 
for the conventionally loaded MMF (Figure 4.3). By the end of six hours this increase in 
drug release is still evident (35 % vs 72 %). This increased drug release rate could also 
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be attributed to differences in molecular interactions as identified by molecular 
mechanistic studies previously reported30. Introduction of SLNs into the polymeric film 
matrix could make the previously identified quadra-molecular architecture between the 
two co-blended polymers and plasticizers, less stable30. This could lead to an increase 












Figure 4.3:  Comparison of DDI release from conventional MMFs30 and nano-enabled 
MMFs.  
 
Complete drug release from the nano-enabled films was not achieved over the 6 hour 
testing period (72 %). This could be attributed to incomplete dissolution of the film in 
the dissolution media, which is related to the low aqueous solubility of EUD. This would 
prevent free and deep water penetration into the film, thereby only allowing the DDI 
near the external surface of the film to be released61. Incomplete drug release related 
to EUD solubility is applicable to the conventionally loaded portion of the drug in the 
film. Another possible theory for incomplete drug release being achieved over the 6 
hour period is that approximately 16 % of DDI in the nano-enabled formulation was 
entrapped inside the SLNs, which would release the drug over a prolonged period of 
time (days), whilst circulating in the body. In a recent study on nano-enabled films for 
lysozyme delivery33 drug release of 50 % over a 4 hour period was achieved, which 
corresponds with our study. In another study, it was found that 40 % of insulin was 
released  from PEG-b-PLA nanoparticles entrapped in chitosan films, over the initial 6 
hour testing period after which this was followed by a constant and complete sustained 
release over 5 weeks32. From our results it can be concluded that the incorporation of 
SLNs into MMFs intended for buccal drug delivery, alters the rate of drug release 
achieved with conventional films by possible changes in the film structure.  
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Since only 16 % of drug is entrapped into the SLNs, the majority of the drug is 
dispersed in its free form in the film matrix. Although drug entrapment is low, the 
presence of SLNs does indeed affect the film characteristics. This is evident by the 
changes in drug release, mucoadhesion and mechanical properties etc. Although faster 
drug release occurred due to the possible effect of the SLNs on the matrix film 
structure, drug release from the nano-enabled films could have been further sustained 
for prolonged periods if higher drug entrapment values are obtained. This aspect could 
be the focus of subsequent studies. 
 
3.5.3  In Vitro Permeation 
 
The buccal permeability of DDI incorporated into films was investigated (Figure 4.4). 
The non-linear portion of the plot was considered as the time required for steady state 
permeation (Jss) to be achieved. In both cases, a time of 45 minutes was observed, 
which is related to the polymeric film matrix entrapping the drug, as well as the mucosal 
membrane serving as a barrier to drug permeation. Although the buccal mucosa acts 
as a barrier because of its anatomical structure and thickness, a conventional lag time 
is not observed in this study (Figure 4.4) and some drug is able to permeate within the 
first 15 min. This could be due to permeation of DDI (hydrophilic) through the 
paracellular pathway. Similar lack of lag times during buccal permeation studies with 
porcine mucosa has been reported previously by Rao et al37. They postulated that with 
the increase in apparent solubility (due to milling of phenylephrine), more dissolved 
drug is present at the porcine buccal mucosal surface, resulting in a higher 
concentration gradient across the mucosa. Since DDI permeates through buccal 
mucosa via passive diffusion16, the increase in the concentration gradient across the 
membrane contributed to the observed permeability of DDI and the apparent absence 
of observed lag time. 
 
Furthermore, DDI is an amphoteric compound that has a weakly acidic hydrogen atom 
on the hypoxanthine moiety and a number of basic nitrogen atoms77. An unionized form 
of a drug more readily interacts with lipid membranes than a drug in the ionized form. 
Under buccal permeation conditions (pH 6.8), amphoteric nucleoside analogues such 
as DDI may be kept in their unionized forms and the permeation of them may be 
promoted. 
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In this study, we show that the drug can be released from the buccal film and can 
permeate across the mucosa as evidenced by permeability coefficients of 0.72 ± 0.14 × 
10−2cm/h and 0.74 ± 0.16 × 10−2cm/h, and steady state flux (Jss) values of 71.63 ± 
13.54 µg/cm2h and 74.39 ± 15.95 µg/cm2h, for the conventional and nano-enabled 
MMFs, respectively (Table 4.7). The flux value of the nano-enabled films was only 











Figure 4.4:  Comparison of cumulative amount of DDI permeated per unit surface area 
versus time from conventional MMFs30 and nano-enabled MMFs.  
 
Although the steady state flux values (p = 0.775) and permeability coefficients (p = 
0.806) did not significantly increase, the cumulative amount of DDI permeated per unit 
surface area increased by 23.54 % (p = 0.161) by using nano-enabled MMFs. This 
could be related to the increased drug dissolution as explained in section 3.5.2 seen for 
nano-enabled MMFs. The relatively low entrapment efficiency (15.8 %) of DDI into 
SLNs reported in this study could have also contributed to the insignificant increase in 
buccal permeability as found during the 6 hour in vitro permeation study. It is quite 
possible that DDI entrapped into the SLN would take extended periods of time (> 6 
hours) to release entrapped drug in an aqueous environment.  
 
DDI is a hydrophilic drug and has been reported to have an aqueous solubility of 27.3 
mg/mL78. The solubility properties of the drug ensured that sink conditions were 
maintained during permeation studies. Solubility facilitated release and permeation of 
the drug through the mucosa. Drugs with poor aqueous solubility such as saquinavir 
mesylate79 or phenylephrine37 requires modification via ball milling to achieve desired 
buccal permeation. 
 
However, this study importantly confirmed that the use of SLNs to deliver the drug 
(DDI) via the buccal mucosa did not adversely affect the flux and confirms the potential 
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of DDI being delivered via the buccal route using nano-enabled MMFs. To the best of 
our knowledge this is the first paper examining the buccal permeability of a drug 
entrapped in a lipid based nanoparticulate system, formulated into a mucoadhesive 
film; therefore no information is available to validate our hypothesis against.  
 
Table 4.7: Permeability parameters for DDI entrapped in MMFs. 
 









of DDI permeated  
(µg/cm2) 
  MEAN ± SD MEAN ± SD MEAN ± SD 
CD Conventional films30 71.63 ± 13.54 0.72 ± 0.14 496.71 ± 82.45 
CP Nano-enabled films 74.39 ± 15.95NS 0.74 ± 0.16NS 613.63 ± 147.77NS 
Statistical significance compared to conventional films - *** p < 0.001; ** p 0.001 to 0.01; * p 0.01 to 0.05;  
NS p > 0.05 
 
Holpuch et al. demonstrated the feasibility of oral transmucosal nanoparticle delivery 
for systemic drug delivery80. Their study was done using human oral explants and 
idarubicin-loaded SLNs and they found that SLNs approximately 200 nm in size and 
negatively charged can penetrate through the epithelium and basement membrane into 
the underlying connective tissue, making systemic drug delivery using SLNs feasible 
via the buccal route.  Therefore the possibility for enhanced ARV delivery via the 
buccal mucosa using SLNs exists and clearly need further exploration and formulation 
development. 
 
3.5.4  Mucoadhesivity of Films 
 
Conventional MMFs exhibited higher mucoadhesion (1425.00 ± 77.15 mN) than nano-
enabled MMFs (914.33 ± 68.09 mN) (Table 4.8). This can be attributed to the higher 
degree of molecular binding possible between the polymers of the conventional films 
and the mucin30 than occurring between the polymers, mucin and SLNs. Nano-enabled 
films displayed significantly reduced mucoadhesion (p = 0.007), a trend which was also 
apparent in a recent study on nano-enabled films for lysozyme delivery33. 
 
It was observed that in the presence of DDI the mucoadhesive force required to detach 
the film, decreased (1992.11 ± 130.04 mN to 1353.67 ± 127.02 mN) and can be 
attributed to increased molecular interactions possible between the drug and the 
polymer30,33. Reduced mucoadhesion found in this study for drug loaded MMFs 
compared to placebo MMFs have also been reported for buccal bilayer patches 
containing pravastatin sodium81 and buccal tablets containing testosterone82. 
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Table 4.8: Mucoadhesive properties of films. 
Type of  
Buccal Film 
Maximum  
Detachment Force  
(mN)  
n=9 
Work of Adhesion  
(mJ)  
n=9 
  MEAN ± SD CV % MEAN ± SD CV % 
CP Conventional Drug Free 1992.11 ± 130.04 6.53 1.59 ± 0.25 15.95 
CD Conventional  Drug Loaded30 
1425.00 ± 77.15 5.41 1.21 ± 0.32 26.18 
NP Nano-enabled Drug Free 1353.67 ± 127.02 9.38 0.61 ± 0.20 32.26 
ND Nano-enabled Drug Loaded 914.33 ± 68.09 7.45 0.59 ± 0.08 14.29 
 
3.5.5  Mechanical Testing 
 
The mechanical properties of conventional and nano-enabled films were evaluated and 
the data is presented in Table 4.9. The greater elasticity, tensile strength and 
toughness demonstrated by conventionally loaded DDI films may be related to the 
increased degree of cross-linking possible in the film matrix83,84. As seen with 
mucoadhesion studies, the incorporation of SLNs into MMFs also decreased the 
mechanical properties of the films. This finding differs from a reported study on PEG-b-
PLA copolymeric nanoparticles embedded in chitosan films32. In their, case molecular 
interactions or cross-linking between the polymeric nanoparticles and polymeric film 
may have been increased, resulting in increased tensile strength and Young’s modulus 
for nano-enabled films. However, tensile strength of drug loaded nano-enabled MMFs 
(0.4930 N/mm2) compares favourably to nano-enabled films prepared previously38, 
indicating that the nano-enabled MMFs in this study have the necessary strength to 
withstand forces encountered during handling and use. 
 
Table 4.9: Mechanical properties of films. 
Type of  
Buccal Film 
Rupture 
















  MEAN ± SD MEAN ± SD MEAN ± SD MEAN ± SD MEAN ± SD 
CP Conventional Drug Free 7.38 ± 0.13 0.7150 ± 0.052 0.43 ± 0.05 60.72 ± 3.47 80.65 ± 10.82 
CD Conventional  Drug Loaded30 6.69 ± 0.39 0.6976 ± 0.064 0.23 ± 0.05 69.54 ± 7.77 111.70 ± 12.98 
NP Nano-enabled Drug Free 4.94 ± 0.27 0.5453 ± 0.019 0.30 ± 0.03 57.30 ± 11.08 58.26 ± 12.53 
ND Nano-enabled Drug Loaded 3.35 ± 0.38 0.4930 ± 0.003 0.24 ± 0.03 72.10 ± 8.06 58.96 ± 19.13 
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The aim of the study was to design and evaluate novel nano-enabled polymeric films 
for buccal delivery of DDI as a model ARV drug. The objectives were to identify optimal 
parameters for preparation of DDI loaded SLNs, and to prepare and compare the 
physico-mechanical properties of nano-enabled MMFs with conventionally prepared 
MMFs. In this study DDI was incorporated in SLNs for the first time, using a hot 
homogenization and ultrasonication technique. The optimal DDI SLNs consisted of 
glyceryl tripalmitate as lipid with Poloxamer 188 as surfactant and exhibited desired 
particle size (201 nm), PDI (0.168), zeta potential (-18.8 mV) and a formulation pH 
(5.5). Identified SLN formulations were incorporated in monolayered multipolymeric 
buccal films and resulting films were evaluated. In vitro buccal permeability studies 
indicates that the use of SLNs to deliver DDI via the buccal mucosa did not adversely 
affect the flux and confirms the potential of DDI being delivered via the buccal route 
using nano-enabled MMFs. SLN incorporation into the films decreased the in vitro 
mucoadhesiveness and mechanical properties and could be attributed to decreased 
molecular interactions between the polymers and mucin upon entrapment of SLNs into 
the film matrix. In vitro drug release of DDI from nano-enabled films was higher as 
compared to conventionally drug loaded MMFs. The data obtained in the study 
demonstrated for the first time the potential of DDI SLN preparation and nano-enabled 
SLN buccal polymeric films to serve as platforms for delivery of an antiretroviral drug, 
DDI. These physico-mechanical evaluations have confirmed the use of nano-enabled 
MMFs containing DDI SLNs prepared with glyceryl tripalmitate and Poloxamer 188 
entrapped in films consisting of HPMC and EUD, as a potential buccal drug delivery 
system to enhance patient therapy. These studies further serve as a platform for future 
investigations to statistically optimize the formulations for simultaneous enhancement 
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CHAPTER FIVE 
GENERAL CONCLUSIONS AND  
RECOMMENDATIONS FOR FUTURE STUDIES 
 
5.1  GENERAL CONCLUSIONS 
 
Whilst ARVs have proven to be useful in the treatment and management of HIV & 
AIDS, several disadvantages limit their efficacy. Novel drug delivery systems and 
alternative routes to deliver ARVs are being explored to overcome these limitations. To 
date, studies reporting on the delivery of ARVs via the buccal route remain limited. 
ARV buccal drug delivery systems have not been comprehensively investigated or 
characterised, and a clear need exists for formulation optimization in this field.  
 
The aim of the study was therefore to design, evaluate and optimize the preparation of 
novel polymeric films for buccal delivery of DDI as a model ARV drug. Thus, the 
objectives of the study were to 1) identify optimal process and formulation variables for 
the preparation of MMFs containing DDI; 2) evaluate the films in terms of of drug 
content uniformity, drug release, permeability, mucoadhesivity, mechanical properties 
and surface pH; 3) perform static lattice atomistic simulations (SLAS) to identify the 
suitability of the polymeric blend for buccal film formulations and to identify correlations 
between in vitro and in silico results (IVIS); and 4) undertake preliminary formulation 
studies on nano-enabled polymeric films for buccal delivery of DDI. The following 
conclusions were generated from the various experiments in this study: 
 
• In the first phase of this study, MMFs with co-blended polymers of opposing 
solubilities and DDI were prepared in various polymeric ratios and extensively 
characterized. A simplified solvent casting/evaporation technique that 
eliminated the need for homogenization and cooling, carcinogenic solvents and 
additional emulsifiers was developed for this purpose. Buccal films containing 
DDI were successfully prepared via co-blending of HPMC and EUD. Drug 
content was uniform (CV < 6 %) and within required specifications (91 % to 105 
%). Controlled release of DDI from MMFs was obtained by modifying the ratios 
of HPMC and EUD while an increase in HPMC led to an increase in drug 
release yet still maintained controlled release profiles with no significant dose 
dumping (33 % within the 1st hour for 1:1:10).  Formulations exhibiting desired 
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controlled drug release and drug content uniformity had acceptable mechanical 
strength and mucoadhesivity.  The buccal permeability potential of DDI from 
polymeric films was successfully demonstrated for the first time as evidenced 
by a permeability coefficient of 0.72 ± 0.14 x10-2 cm/h and a steady state flux 
(Jss) value of 71.63 ± 13.54 µg/cm2h.  Histomorphological studies confirmed no 
buccal tissue damage or distress on exposure to drug loaded MMFs. The 
transepithelial electrical resistance (TEER) values obtained were within the 
reported range and the overall percentage change also indicated that mucosal 
integrity was not irreversibly affected. The data obtained in the first phase of the 
study demonstrated for the first time the potential of buccal polymeric films to 
serve as platforms for delivery of DDI.  
 
• SLAS were preformed to identify the suitability of the polymeric blend for buccal 
film formulations and to identify correlations between in vitro and in silico results 
(IVIS) obtained in the first phase above. SLAS provided a mechanistic 
understanding of the molecular interactions involved in film formation and 
confirmed the corroboration of the in silico and in vitro mucoadhesive and drug 
release experimental data. The SLAS results indicated that HPMC and EUD as 
polymers in combination with glycerol and trietyl citrate as plasticizers formed a 
stable quadra-molecular system with the total energy of stabilization being six 
times higher than that of only the polymers in combination. It thereby supported 
the choice of polymers and plasticizers for the “novel co-blending-co-plasticizing 
strategy” employed in this study. Molecular mechanistic simulations also 
provided additional supportive information to understand drug release profiles 
and mucoadhesion when blending polymers of opposing solubilities. The SLAS 
studies therefore provided useful quantitative information to simultaneously 
predict the stability of polymeric and plasticizer film blends and to also identify 
the potential mechanisms for the observed drug release and mucoadhesion. 
 
• The final phase of this study involved the preparation and evaluation of novel 
nano-enabled MMFs for buccal delivery of DDI as a model ARV drug. Optimal 
parameters for preparation of DDI loaded SLNs were identified before 
incorporation of the SLNs into nano-enabled MMFs which were subsequently 
compared to conventionally prepared DDI MMFs. In this study DDI was 
incorporated into SLNs for the first time, using a hot homogenization and 
ultrasonication technique. The optimal DDI SLNs consisted of glyceryl 
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tripalmitate as the lipid with Poloxamer 188 as the surfactant. The highest drug 
entrapment efficiency (18 %) was achieved with a drug loading of 1.2 % w/v. 
Identified SLN formulations were incorporated into monolayered multipolymeric 
buccal films and the resulting films were evaluated similarly as to the first phase 
of the study. In vitro buccal permeability studies indicated that the use of SLNs 
to deliver DDI via the buccal mucosa did not adversely affect the flux and 
confirmed the potential of DDI being delivered via the buccal route using nano-
enabled MMFs. Future approaches to increase EE may result in significantly 
increased buccal permeability. SLN incorporation into the films decreased the in 
vitro mucoadhesiveness and mechanical properties. In vitro drug release of DDI 
from nano-enabled films was higher as compared to conventionally drug loaded 
MMFs, and shows potential for sustained drug release with further modification. 
The data obtained in the study demonstrated for the first time the potential of 
nano-enabled buccal polymeric films to serve as platforms for delivery of DDI. 
These studies further serve as a platform for future investigations to statistically 
optimize the formulations for simultaneous enhancement of drug entrapment, 
drug release, permeation, mucoadhesion and mechanical strength.  
 
The findings of this study have contributed significantly to the field of novel drug 
delivery systems. The formulation strategies developed and the in depth 
characterisation studies undertaken will be useful to formulation scientists for 
optimising the development of buccal delivery systems for enhancing drug therapy and 
patient outcomes. Further studies in this promising filed will require a multidisciplinary 
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5.2  RECOMMENDATIONS FOR FUTURE STUDIES  
 
This study has laid the groundwork for formulating ARVs into a convenient and 
effective buccal delivery system. Further studies are essential prior to 
commercialisation of the buccal films and can be summarized as follows: 
 
• A design of experiments approach must be used for optimising the formulation 
variables in terms of polymer combinations for the preparation of the MMFs. A 
design of experiments approach i.e. Response surface modelling will 
systematically identify the ideal polymeric blends for providing both 
mucoadhesivity and controlled drug release and also facilitate an understanding 
of the inter-relationship among and between formulation and process variables 
for the preparation of DDI loaded films. This understanding will allow the 
determination of the quantitative influence of polymers and plasticizers on drug 
delivery rates, mucoadhesion and mechanical properties. 
 
• Permeation studies with enhancers included in the formulation as well as 
cytotoxicity studies should be considered. Penetration enhancers such as bile 
salts, surfactants, fatty acids alter the permeability the buccal mucosa thereby 
improving drug delivery through the buccal mucosa. Drug delivery through the 
buccal mucosa is limited by the barrier properties of the epithelium and 
inclusion of permeation enhancers can allow for delivery of therapeutically 
relevant amounts of drug to the systemic circulation. Cytotoxicity studies on 
buccal cell lines would provide useful information regarding the safety of use of 
the films in the human oral cavity. 
 
• Short- and long-term chemical and physical stability studies to assess the 
stability of the DDI-loaded MMFs generated should be undertaken to confirm 
the quality of the product as well as to assess alterations in drug stability, drug 
release and mucoadhesion of the system. Stability studies under ICH guidelines 
to determine shelf life and suitable storage conditions can be done.  This testing 
should include conditions of accelerated temperatures and cover an appropriate 
pH range since DDI is known to undergo degradation in acidic conditions, its 
solubility has been reported to be pH-dependant.  
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• Additional film characterization can include evaluation using advanced 
techniques such as XRD, TGA, DSC and FTIR. The physical form of drug 
molecules inside the MMFs can be easily determined by XDR analysis. This 
would provide information on whether the drug is present in crystalline or 
amorphous form in the film and it is of importance since the physico-chemical 
properties would be influenced. DSC analysis can provide insight into the state 
of the drug molecules inside the MMFs. Useful information regarding phase 
transitions, recrystallization or molecular interactions of the drug molecule 
entrapped inside the MMFs can be obtained. Drug-polymer interaction can be 
detected via FTIR and can be used to assess the compatibility of drug with the 
excipients. This would allow for a better understanding of DDI compatibility with 
polymers identified previously as suitable for combined use via SLAS. 
 
• In vivo studies using animals and human subjects should be performed to 
further test the formulation in terms of retention time of the dosage form on the 
mucosa. In vivo studies using suitable animal models will also provide 
information on bioavailability and related pharmacokinetic parameters which in 
turn would provide insight into suitable formulation modifications that would be 
required to achieve optimal bioavailability. Bioavailability studies may also 
provide useful comparative information against other currently available per oral 
formulations of DDI. 
 
• A larger scale production method could be designed for the preparation of the 
MMFS in order to assess the feasibility of the film preparation method for 
application in the pharmaceutical industry. A prerequisite for new formulations 
into the pharmaceutical industry is the availability of a suitable large-scale 
production method. The method should be qualified, validated and cost-
effective. Additionally, the method should yield a preparation that is of 
acceptable quality that allows registration by the relevant regulatory authorities. 
Furthermore, large-scale production methods have been established for 
microparticles, but remain to be established for many nanoparticles. 
 
• For nano-enabled films specifically several future studies can be considered. 
The drug entrapment efficiency (EE) for hydrophilic drugs remains problematic 
as also seen in this study and future work should specifically focus on 
optimizing the EE. Methods to further increase drug entrapment of DDI into 
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SLNs or incorporation of only separated SLNs into the MMFs may improve 
buccal permeability if DDI. Stability studies on SLNs and nano-enabled films as 
well as investigations using techniques such as DSC may provide useful 
information of the nature of the drug in these kinds of novel preparations. The 
compatibility and suitability of excipients can also be confirmed. Imaging of 
nano-enabled films via SEM/TEM to visualize the entrapped nanoparticles can 
be considered. Molecular mechanistic simulations can be done on the nano-
enabled film components to establish a corroboration between the in silico and 
in vitro experimental data upon inclusion of SLNs into the MMFs. Future work 
will also require polymeric modification of the base film components in order to 
achieve enhanced mucoadhesion and desirable drug release for nano-enabled 
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